Ghrelin Gene Products and the Regulation of Food Intake and Gut Motility

CHIH-YEN CHEN, AKIHIRO ASAKAWA, MINEKO FUJIMIYA, SHOU-DONG LEE, AND AKIO INUI

Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei (C.-Y.C, S.-D.L.), and Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (C.-Y.C, S.-D.L.); Department of Anatomy, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan (M.F.); and Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (A.A., A.I.)

Abstract............................................................................... 431

I. Introduction: discovery of growth hormone secretagogue receptor, ghrelin gene products (Acyl ghrelin, des-acyl ghrelin, and obestatin), and ghrelin O-acyltransferase ................................................... 431

II. Normal physiology of acyl ghrelin and regulation of its expression and interactions .............................................. 433

A. Regulation of food intake by acyl ghrelin .............................................. 433
B. Regulation of whole-body energy homeostasis by acyl ghrelin ...................... 434
C. Regulation of mucosa protection by acyl ghrelin ........................................ 434
D. Regulation of water intake by acyl ghrelin ............................................ 435
E. Regulation of gastrointestinal motility and gastric acid secretion by acyl ghrelin ......................................................... 435
F. Regulation of acyl ghrelin secretion ................................................... 435
G. Interactions between acyl ghrelin and other neuropeptides ...................... 436

III. Normal physiology of des-acyl ghrelin and regulation of its expression and interactions ............................................. 438

IV. Normal physiology of obestatin and regulation of its expression and interactions ......................................................... 438

V. Normal physiology, expression, and regulation of growth hormone secretagogue receptor .................................................. 439

VI. Normal physiology, expression, and regulation of ghrelin O-acyltransferase .................................................................... 440

VII. Pathophysiology of ghrelin gene products in feeding and body weight regulation ................................................................. 441

A. Relationships between plasma levels of ghrelin gene products and body weight homeostasis ................................................. 441
B. Acyl ghrelin in feeding and body weight regulation .................................... 441
C. Interactions between ghrelin gene products and the blood-brain barrier .......... 442
D. Interactions between acyl ghrelin and Helicobacter pylori on feeding ....... 443
E. Total acyl ghrelin and burn injury ................................................................ 443
F. Growth hormone secretagogue receptor agonist and postoperative anorexia-cachexia ........................................ 443
G. Total acyl ghrelin and functional dyspepsia ........................................... 443
H. Acyl ghrelin, reward feeding, and related body weight regulation .............. 443

VIII. Normal physiology and pathophysiology of ghrelin gene products in feeding-associated gastrointestinal motility .................................................................................. 444

IX. Access of ghrelin gene products to the central nervous system: direct and indirect neuroendocrine pathways .......................................................... 448

X. Direct effects of ghrelin gene products on other tissues ............................. 450

A. Glucose metabolism .............................................................................. 450
B. Lipid metabolism .................................................................................. 453
C. Cardiovascular system ........................................................................... 454
D. Endocrine system .................................................................................. 455
1. Hypothalamic-pituitary-adrenal axis ...................................................... 455
2. Hypothalamic-pituitary-thyroid axis ...................................................... 455
E. Cell proliferation .................................................................................... 455
F. Immune function .................................................................................... 456
G. Bone metabolism .................................................................................. 457
H. Sleep ..................................................................................................... 457

Address correspondence to: Dr. Akio Inui, Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520 Japan. E-mail: inui@m.kufm.kagoshima-u.ac.jp
This article is available online at http://pharmrev.aspetjournals.org.

2009 by the American Society for Pharmacology and Experimental Therapeutics
Pharmacol Rev 61:430–481, 2009
GHRELIN GENE PRODUCTS IN FOOD INTAKE & GUT MOTILITY

I. Memory.................................................................458
J. Anxiety behavior ..................................................459

XI. Disturbance of energy homeostasis in various conditions: roles of ghrelin gene products in obesity and anorexia-cachexia ..................459
A. Obesity .....................................................................459
B. Anorexia and cachexia ..............................................462
1. Cancer anorexia-cachexia syndrome .......................462
2. Noncancerous anorexia-cachexia. .........................464
   a. Psychogenic: anorexia nervosa .........................464
   b. Nonpsychogenic: chronic heart failure, chronic obstructive pulmonary disease, liver cirrhosis, and chronic kidney disease. ..........466

XII. Therapeutic approaches to affecting the ghrelin system: endogenous ghrelin gene products, growth hormone secretagogue receptor 1a, and ghrelin O-acyltransferase. ..........................469

XIII. Conclusions ..........................................................470
Acknowledgments ..........................................................471
References ...............................................................471

Abstract—A breakthrough using “reverse pharmacology” identified and characterized acyl ghrelin from the stomach as the endogenous cognate ligand for the growth hormone (GH) secretagogue receptor (GHS-R) 1a. The unique post-translational modification of O-n-octanoylation at serine 3 is the first in peptide discovery history and is essential for GH-releasing ability. Des-acyl ghrelin, lacking O-n-octanoylation at serine 3, is also produced in the stomach and remains the major molecular form secreted into the circulation. The third ghrelin gene product, obestatin, a novel 23-amino acid peptide identified from rat stomach, was found by comparative genomic analysis. Three ghrelin gene products actively participate in modulating appetite, adipogenesis, gut motility, glucose metabolism, cell proliferation, immune, sleep, memory, anxiety, cognition, and stress. Knockdown or knockout of acyl ghrelin and/or GHS-R1a, and overexpression of des-acyl ghrelin show benefits in the therapy of obesity and metabolic syndrome. By contrast, agonism of acyl ghrelin and/or GHS-R1a could combat human anorexia-cachexia, including anorexia nervosa, chronic heart failure, chronic obstructive pulmonary disease, liver cirrhosis, chronic kidney disease, burn, and postsurgery recovery, as well as restore gut motility, such as diabetic or neurogenic gastroparesis, and postoperative ileus. The ghrelin acyl-modifying enzyme, ghrelin O-Acyltransferase (GOAT), which attaches octanoyl to serine-3 of ghrelin, has been identified and characterized also from the stomach. To date, ghrelin is the only protein to be octanoylated, and inhibition of GOAT may have effects only on the stomach and is unlikely to affect the synthesis of other proteins. GOAT may provide a critical molecular target in developing novel therapeutics for obesity and type 2 diabetes.

I. Introduction: Discovery of Growth Hormone Secretagogue Receptor, Ghrelin Gene Products (Acyl Ghrelin, Des-Acyl Ghrelin, and Obestatin), and Ghrelin O-Acyltransferase

In 1996, a G protein-coupled receptor was successfully cloned from human and swine pituitary and hypothalamus and was identified as the target of growth hormone (GH) secretagogues (GHS), a class of peptide and non-peptide compounds functioning in GH release from the anterior pituitary (Howard et al., 1996). Nucleotide sequence analysis indicated two subtypes of cDNAs derived from the same gene, located on chromosome 3q26.2 (McKee et al., 1997), which encodes two transcripts: Ia and Ib. An official International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification nomenclature designated growth hormone

1 Abbreviations: 5-HT, 5-hydroxytryptamine; AgRP, agouti-related protein; AMPK, AMP-activated protein kinase; BAPTA, 1,2-bis(2-aminoethoxy)ethane-N,N,N',N'-tetraacetic acid; CART, cocaine- and amphetamine-regulated transcript; CB1-R, cannabinoid receptor subtype 1; CB2-R, cannabinoid receptor subtype 2; CHF, chronic heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRF1-R, corticotropin-releasing factor receptor subtype 1; CRF2-R, corticotropin-releasing factor receptor subtype 2; GHS-R1a, growth hormone releasing hormone; GHS-R1b, growth hormone releasing hormone: GHS-R1a, growth hormone secretagogue receptor 1a; GOAT, ghrelin O-acyltransferase; GSK94281, N-(5-(cis-3,5-dimethyl-1-piperazinyl)-2-(methyloxy)phenyl)-3-fluoro-4-(5-methyl-2-furanyl)benzenesulfonamide; IGF, insulin-like growth factor; L-163,255, N-(1-(1,2-dihydro-1-methanesulfonylspiro[3H-indole-3,4'-piperidine-1'-yl]carbonyl)-4-phenylbutyl)-2-amino-2-methylpropanamide hydrochloride; MC3-R, melanocortin receptor subtype 3; MC4-R, melanocortin receptor subtype 4; MK-677, 2-dihydro-1-ethanesulfonfylspsiro[3H-indole-3,4'-piperidin]-1'-yl]carbonyl-2-(phenylmethoxy)-ethyl-2-aminomethylpropanamide; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; PYY, peptide YY; RT-PCR, reverse transcription-polymerase chain reaction; SHU9119, Ac-Nle(4)-cAsp(5)-2-Nal(7) -Lys(10)-aMSH(4-10)-NH2; SR141716, rimonabant; TM, trans-membrane domain; TNF, tumor necrosis factor; TZIP-101, (4R,7S,10R,13R)-7-cyclopropy1-13-(4-fluorobenzyl)-3-oxa-6,7,9,12,15-tetraaza-4,9,10-trimethyl-4,5,6,7,10,12,13,15,16,17,18-undecahydro-1,2-benzocyclooctadecene-8,11,14-trione; UCP, uncoupling protein.
secretagogue receptor 1a (GHS-R1a) as the acyl ghrelin receptor, abbreviated when necessary to GRLN receptor (Davenport et al., 2005).

In 1999, acyl ghrelin was identified as the endogenous cognate ligand for the growth hormone secretagogue receptor, GHS-R1a (Kojima et al., 1999). The discovery of acyl ghrelin, a 28-amino acid peptide, as the first endogenous ligand for a GHS-R (previously known as an orphan receptor) isolated from the stomach, involves the idea and technique of “reverse pharmacology” (Kojima et al., 1999). Acyl ghrelin acts on GHS-R1a to stimulate GH release, which is distinct from its stimulation by hypothalamic GH-releasing hormone (GHRH). Acyl ghrelin features a unique post-translational modification of O-n-octanoylation at serine 3, and the post-translational modification of octanoylation is the first in peptide discovery history (Kojima et al., 1999; Kojima, 2008). The second endogenous cognate ligand for GHS-R, des-Gln1-ghrelin, another novel 27-amino acid peptide, is created by alternative splicing of the ghrelin gene, and constitutes one fifth of ghrelin immunoreactivity of the rat stomach. It is as potent as ghrelin for stimulation of GH secretion (Hosoda et al., 2000a). In addition to stimulating GH secretion (Kojima et al., 1999; Seoane et al., 2000; Wren et al., 2000; Brogli et al., 2001), a unique post-translational modification of O-n-octanoylation at serine 3 of ghrelin is also indispensable for acyl ghrelin’s ability to enhance food intake (Wren et al., 2000, 2001a,b; Druce et al., 2005; Druce et al., 2006) and adiposity (Tschöp et al., 2000; Wren et al., 2001b) in humans and rats. To date, acyl ghrelin is the only peripheral hormone that increases meal size (Woods, 2004; Chen et al., 2008c). Finally, acyl ghrelin and GHRH are both endogenous GH-releasing peptides. GHRH acts on the GHRH receptor, distinct from GHS-R1a, to activate adenylate cyclase and increase intracellular cAMP, which serves as a second messenger to activate protein kinase A (Kojima and Kangawa, 2005).

In contrast, des-acyl ghrelin, lacking O-n-octanoylation at serine 3, is also produced in the stomach and remains the major molecular form secreted into the circulation. Plasma des-acyl ghrelin/acyl ghrelin ratio ranges from 2.5:1 (Broglio et al., 2004c), 3:1 (Garcia et al., 2002) from different studies. At first, des-acyl ghrelin was regarded as a nonfunctional ghrelin ligand. Des-acyl ghrelin has been shown to actively participate in food intake (Asakawa et al., 2005; Chen et al., 2005a,b; Matsuda et al., 2006; Toshinai et al., 2006; Muscaritoli et al., 2007; Inhoff et al., 2008; Stengel et al., 2008), gut motility (Asakawa et al., 2005; Chen et al., 2005a,b), body size development (Ariyasu et al., 2005; Asakawa et al., 2005), adipogenesis (Thompson et al., 2004), insulin secretion and resistance (Broglio et al., 2004b; Gauna et al., 2004, 2005, 2007; Iwakura et al., 2005; Qader et al., 2008; Zhang et al., 2008b; Kiewiet et al., 2009), to increase tension of guinea pig papillary muscle ex vivo (Bedendi et al., 2003), and cell proliferation and survival in vitro (Baldanzi et al., 2002; Cassoni et al., 2004, 2006; Granata et al., 2006, 2007; Filigheddu et al., 2007). A more recent study revealed that des-acyl ghrelin was secreted in a highly regulated manner in response to food deprivation in mice (Kirchner et al., 2009). Hence, des-acyl ghrelin should not only be an “innocent bystander,” especially after the discovery of ghrelin O-acetyltransferase (GOAT). Des-acyl ghrelin is speculated to bind to an additional as-yet unidentified receptor different from GHS-1a. However, it is ambiguous whether the effects of des-acyl ghrelin are direct or not.

The third ghrelin gene product, obestatin, a novel 23-amino acid peptide identified from rat stomach, was derived from the mammalian prepro-ghrelin gene, which also encodes ghrelin, by comparative genomic analyses (Zhang et al., 2005). It was originally projected that obestatin binds to an orphan G protein-coupled receptor, termed GPR39, to inhibit food intake (Zhang et al., 2005). However, the effects of obestatin on food intake remain debatable. On the other side, obestatin manifested various biological functions, such as improving memory performance, causing anxiolytic effects (Carlini et al., 2007b), inhibiting thirst in rats (Samson et al., 2007), activating cortical neurons (Dun et al., 2006), stimulating proliferation of retinal pigment epithelial cells in vitro (Caminha et al., 2007), and profoundly influencing sleep (Szentirmai and Krueger, 2006b; Szentirmai et al., 2009).

Serine-3 of ghrelin, which is acylated with an eight-carbon fatty acid, octanoate, is inextricably required for the multifaceted endocrine functions of acyl ghrelin. Despite the crucial role for octanoylation in the physiology of ghrelin, the lipid transferase that mediates this novel modification had remained unknown until 2008. In 2008, ghrelin O-acetyltransferase (GOAT), attaching octanoate to serine-3 of ghrelin, was identified and characterized by two independent research groups (Yang et al., 2008a; Gutierrez et al., 2008). Ghrelin seems the sole substrate for GOAT (Yang et al., 2008a). GOAT is located in the endoplasmic reticulum, and the presumed donor for octanoylation is octanoyl-CoA (Yang et al., 2008a). Expression of GOAT was demonstrated to be limited to the gastrointestinal tract, intestine, testis (Yang et al., 2008a), and the pancreas (Gutierrez et al., 2008), the major ghrelin-secreting tissues. The discovery of GOAT, an enzyme specific for octanoylation of ghrelin, identified the mechanism for this unique derivatization of ghrelin and also holds the promise of answering some major questions about the unanswered but important physiological roles of ghrelin (Gardiner and Bloom, 2008). The sequential steps of the production of three ghrelin gene products and their relationships with GOAT are illustrated in Fig. 1.
II. Normal Physiology of Acyl Ghrelin and Regulation of Its Expression and Interactions

Acyl ghrelin is recognized to stimulate GH release. When administrated intravenously, acyl ghrelin elicits a marked stimulatory effect on GH secretion (Seoane et al., 2000). Studies from humans and in vitro organ culture systems showed that GH, somatostatin, and cortistatin, but not GHRH or IGF-1, directly inhibit acyl ghrelin secretion (Kojima et al., 1999; Broglio et al., 2002b; Seoane et al., 2007a). These results illustrate the stimulatory effect of acyl ghrelin on GH release and negative feedback control of GH and somatostatin on gastric acyl ghrelin secretion. In addition to affecting on GH release, intravenous administration of acyl ghrelin induced elevation of circulating somatostatin and pancreatic polypeptide concentrations, whereas suppressed plasma insulin levels accompanied hyperglycemia in humans (Arosio et al., 2003). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascularly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascu larly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascularly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascularly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascularly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascularly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009). Ex vivo measurement of the release of acyl ghrelin and des-acyl ghrelin in vascularly perfused rat stomach showed that the release of des-acyl ghrelin from the perfused stomach was greater at pH 2 than at pH 4, whereas the release of acyl ghrelin was not affected by intragastric pH (Mizutani et al., 2009).

Fig. 1. Diagram illustrates sequential steps of the production of three ghrelin gene products and their relationship with GOAT.

A. Regulation of Food Intake by Acyl Ghrelin

Acyl ghrelin acts as a signal for mealtime hunger and meal initiation; to date, it is the only known gastrointestinal peptide to stimulate appetite and increases meal size, among dozens of enzymes, hormones, and other factors secreted by the gastrointestinal tract in response to food in the lumen (Woods, 2004; Chen et al., 2008c). In fact, fasting induced the elevation of acyl or total ghrelin in mice (Kirchner et al., 2009) and rats (Guo et al., 2008), whereas refeeding restored it. In humans, preprandial rise (Cummings et al., 2001; Natalucci et al., 2005; Liu et al., 2008) and postprandial fall (Tschöp et al., 2001a; Natalucci et al., 2005; Liu et al., 2008) in plasma ghrelin levels support the concept that...
ghrelin plays a physiological role in meal initiation. It is noteworthy that short- and long-term exogenous injection of central and peripheral acyl ghrelin induced hyperphagia in rats (Wren et al., 2001a,b), and short-term exogenous administration of acyl ghrelin accelerated gastric emptying and elicited hunger in normal-weight humans (Levin et al., 2006), as well as stimulating energy intake in lean human volunteers (Druce et al., 2005; Druce et al., 2006). In addition to increasing caloric intake, central administration of acyl ghrelin preferentially enhanced fat ingestion in rats (Shimbara et al., 2004). However, we need to be cautious upon data interpretation because of the possibility of leakage into periphery during central injection at higher dosage. Finally, long-term or repeated injection of acyl ghrelin enhances food intake in rats and humans under pathological conditions: counteracting body weight loss in rats implanted with malignant tumor (Hanada et al., 2003), improving appetite and food intake in patients with cancer (Neary et al., 2004), stimulating appetite in humans with chronic wasting diseases, such as chronic obstructive pulmonary disease (Nagaya et al., 2005) and chronic kidney disease (Ashby et al., 2009), and increasing energy intake in patients receiving dialysis (Ashby et al., 2009).

In vivo and ex vivo animal studies in rats revealed that “anticipation of eating,” as well as fasting/feeding status, influenced pre-and postprandial plasma ghrelin levels in rats (Drazen et al., 2006; Seoane et al., 2007b). A novel organ-culture model of gastric tissue explants from rat donors demonstrated that fasting induced gastric ghrelin release, whereas refeeding fully reversed it (Seoane et al., 2007b). The ex vivo experiments also showed that when animals were allowed 15 min before explant extraction to see or smell, but not eat, the food, total ghrelin secretion was suppressed just like in gastric explants from refed rats (Seoane et al., 2007b), whereas this effect was blocked by surgical vagotomy or atropine sulfate. These results indicate that sensorial stimuli related to food, but without food ingestion (tease feeding), are able to modulate gastric ghrelin secretion and circulating ghrelin levels. The food-related stimuli are vagal cholinergic pathway-dependent and mediated by a medium-term memory mechanism from the system of sensory neurons integrated in the enteric nervous system (Seoane et al., 2007b). These findings suggest a role for total ghrelin in the regulation of anticipatory processes involved in food intake and nutrient disposition, independent of nutrient status. However, a human study observed preprandial increases and postprandial suppression of plasma total ghrelin levels among human subjects initiating meals voluntarily, in the absence of time- and food-related cues, as well as a close overlap between the temporal profiles of total ghrelin levels and hunger scores, consistent with the hypothesis that ghrelin functions as an important physiological meal initiator (Cummings et al., 2004). The discrepancies may result from species differences.

B. Regulation of Whole-Body Energy Homeostasis by Acyl Ghrelin

Besides its influence on appetite, acyl ghrelin affects body weight and adiposity. Unlike other gut-derived satiation factors, such as cholecystokinin (which, when administered continuously, changed only meal patterns but not body weight), long-term or repeated injection of acyl ghrelin increased body weight in rats (Wren et al., 2001b) and in humans with chronic wasting conditions, including chronic heart failure (Nagaya et al., 2004) and chronic obstructive pulmonary disease (Nagaya et al., 2005). Central and peripheral administration of acyl ghrelin also decrease energy expenditure in mice and rats, either via increasing respiratory quotient (Tschöp et al., 2000), decreasing oxygen consumption (Asakawa et al., 2001b), suppressing thermogenesis in brown adipose tissue through directly inhibiting brown adipose tissue sympathetic nerve activity (Yasuda et al., 2003), and up-regulating mRNA expression of uncoupling protein 1 (UCP1) in brown fat tissue and uncoupling protein 2 (UCP2) in white adipose tissue (Tsubone et al., 2005), resulting in increase in fat mass. Peripheral exogenous injection with small dose of acyl ghrelin, which did not stimulate food intake, did increase body weight gain and enhance adiposity in mice and rats (Tschöp et al., 2000; Tsubone et al., 2005), indicating that the adiposity-inducing effect of acyl ghrelin is independent of its appetite-stimulating actions. A recent study revealed that during periods of energy insufficiency, exposure to acyl ghrelin may limit energy utilization in specific white adipose tissue depots by GHS-R1a-dependent lipid retention (Davies et al., 2009). Central administration of acyl ghrelin preferentially enhanced fat ingestion in rats (Shimbara et al., 2004), which predisposes the development of obesity.

C. Regulation of Mucosa Protection by Acyl Ghrelin

Acyl ghrelin could be a new gastroprotective factor in gastric mucosa. Increases in the plasma total and acyl ghrelin levels preceded the formation of duodenal ulcers in rats treated with cysteamine, which inhibited the release of somatostatin and induces the formation of duodenal ulcers (Fukuhara et al., 2005). Intracerebroventricular acyl ghrelin dose dependently decreased ethanol-induced gastric ulcers, and the gastroprotective effect of central acyl ghrelin was mediated by endogenous NO release and required the integrity of sensory nerve fibers (Sibilia et al., 2003). Pretreatment with intraperitoneal acyl ghrelin prevented either intragastric ethanol-induced, water immersion and restraint stress-induced, or ischemia-reperfusion-induced gastric mucosal lesions (Brzozowski et al., 2004, 2006; Konturek et al., 2004, 2006), and gastric mucosal expression of tumor necrosis factor α (TNF-α) mRNA (Konturek et al., 2004,
Postprandial acyl ghrelin surges are probably triggered by sympathetic nervous system. Plasma acyl ghrelin levels in rats were increased by a muscarinic agonist, an \( \alpha \)-adrenergic antagonist, and a \( \beta \)-adrenergic agonist, whereas the levels were decreased by a muscarinic antagonist and an \( \alpha \)-adrenergic agonist (Hosoda and Kangawa, 2008). Furthermore, vagotomy inhibited acyl ghrelin secretion in the short term but enhanced it over the long term in rats (Hosoda and Kangawa, 2008). In addition, vagotomy affected neither baseline total ghrelin levels nor the suppression of total ghrelin by a nutrient load in rats (Williams et al., 2003b). The food deprivation-induced elevation of plasma total ghrelin levels was completely prevented by subdiaphragmatic vagotomy, whereas, in a separate experiment, the deprivation-related rise in plasma total ghrelin was substantially reduced by atropine methyl nitrate treatment, indicating that the response to fasting is driven by increased vagal efferent tone (Williams et al., 2003b) and elucidating the dissociation between nutrient load- and deprivation-related ghrelin responses. The results, in turn, indicated that the regulation of circulating total ghrelin levels involved separate mechanisms operating through anatomically distinct pathways. Collectively, acyl ghrelin is modulated by both the cholinergic and adrenergic pathways from the autonomic nervous system. The dissociation between the short- and long-term effects of vagotomy on plasma acyl ghrelin levels implies an additional neural control mechanism involved in the regulation of acyl ghrelin release (Hosoda and Kangawa, 2008). Another study demonstrated that the neural, instead of the neurohumoral, branch of the sympathetic nervous system could directly stimulate total ghrelin secretion in rats (Mundinger et al., 2006). On the other hand, intravenous injection of acyl ghrelin was shown to act on the central nervous system to decrease arterial pressure and renal sympathetic nerve activity in rabbits (Matsumura et al., 2002), demonstrating the participation of central acyl ghrelin in modulating the sympathetic nerve activity to the kidney and the baroreceptor reflex.

Postprandial suppression of plasma ghrelin is not mediated by nutrients in the stomach or duodenum, where most total ghrelin is synthesized and secreted, because either jejunal, gastric, or duodenal nutrient infusions suppressed ghrelin levels (Overduin et al., 2005). The meal-related total ghrelin suppression requires postgastric (pre- or postabsorptive) feedback, because intragastric infusion of glucose did not reduce plasma ghrelin level in rats with occluded pylorus (Williams et al., 2003a). Postprandial suppression of plasma ghrelin is regulated by postmeal increases in lower intestinal osmolarity, circulating insulin surges, and probably blood glucose (Overduin et al., 2005). Furthermore, the depth of postprandial ghrelin suppression was proportional to...
ingested caloric load, but the recovery of plasma ghrelin was not a critical determinant of intermeal interval (Callahan et al., 2004). Moreover, macronutrient type also influences total ghrelin regulation. Glucose and amino acids suppressed ghrelin more rapidly and strongly than did lipids and fructose in rats and women (Teff et al., 2004; Overduin et al., 2005). Electrophysiological recordings revealed that the activity of the glucose-sensing neurons in the nucleus of the solitary tract could be modulated by the acyl ghrelin, and the primary effect of acyl ghrelin on glucose-inhibited and glucose-excited neurons was inhibitory (Wang et al., 2008). The results provide us the mechanisms by which acyl ghrelin diversely influences cellular excitability and neuronal circuitry in the hindbrain, contributing its biological actions to food intake. The suppressive effect on plasma total ghrelin levels by free fatty acids is independent of ambient GH and insulin levels in healthy men (Gormsen et al., 2006). The relatively weak suppression of total ghrelin by lipids and fructose compared with glucose and amino acids could lead to increased caloric intake and contribute to weight gain and obesity during long-term consumption of diets high in lipids and fructose. Two human studies using advanced technique measuring acyl ghrelin confirmed the above findings (Tannous dit El Khoury et al., 2006; Foster-Schubert et al., 2008). It is noteworthy that they found biphasic suppression of plasma ghrelin: a new but intriguing phenomenon featuring an initial decrease in acyl and total ghrelin and a marked rebound above preprandial values of acyl and total ghrelin after carbohydrate ingestion alone (Foster-Schubert et al., 2008), suggesting the mechanisms contributing to the actions of high-protein/low-carbohydrate diets to promote weight loss and high-fat diets to enhance weight gain. The authors theorized that partial substitution of dietary protein for carbohydrate or fat might promote longer-term postprandial acyl ghrelin suppression and satiation (Tannous dit El Khoury et al., 2006). Another study also showed that consumption of a “higher protein-acute meal” led to lower respiratory exchange ratio, lower carbohydrate oxidation, and higher fat oxidation compared with a “normal protein-acute meal,” whereas the “higher protein-acute meal” also led to reduced self-reported postprandial hunger and desire to eat and lower postprandial plasma total ghrelin compared with the normal protein-acute meal in women (Leidy et al., 2007).

G. Interactions between Acyl Ghrelin and Other Neuropeptides.

The hypothalamic arcuate nuclei coexpressing neuropeptide Y (NPY) and agouti-related protein (AgRP), both prototypic anabolic neuropeptides to promote positive energy homeostasis (Schwartz et al., 2000; Seoane et al., 2003; Andrews et al., 2008), are the most well proven central targets for the biological actions of acyl ghrelin. Almost all NPY/AgRP neurons in the arcuate nuclei express GHS-R1a (Willesen et al., 1999; Mondal et al., 2005) (Fig. 2). Short- and long-term injection of acyl ghrelin increased hypothalamic NPY and AgRP mRNA levels with either stimulation of food intake or gain of body weight (Kamegai et al., 2000, 2001). Intrare-
cerebroventricular injection with small doses of acyl ghrelin enhanced food intake without altering the episodic GH release in conscious rats (Kamegai et al., 2000), demonstrating that the feeding-inducing action of acyl ghrelin is independent of its GH-stimulating effect. Acyl ghrelin definitely activates NPY/AgRP neurons in the arcuate nuclei, as shown by the increase of intracellular Ca²⁺ concentration, which was via an AMPK-mediated, protein kinase A- and N-type channel-dependent signaling mechanism (Kohn et al., 2003, 2008) and c-fos immunoreactivity (Hewson and Dickson, 2000; Kamegai et al., 2000, 2001; Shintani et al., 2001; Cowley et al., 2003; van den Top et al., 2004; Chen et al., 2005b; Date et al., 2005; Kobelt et al., 2005; Inhoff et al., 2008) in the arcuate nuclei. Chemical (Tamura et al., 2002), vector-mediated (Bewick et al., 2005), pharmacological (Nakazato et al., 2001; Asakawa et al., 2001b; Keen-Rhinehart and Bartness, 2007), or genetic blockade (Chen et al., 2004; Shaw et al., 2005) of NPY and/or AgRP signaling cascade completely abolished or attenuated the orexigenic effects of acyl ghrelin. Among them, central Y₁ receptor (Asakawa et al., 2001b; Shintani et al., 2001) as well as melanocortin receptor subtype 3 and 4 (MC₃-R and MC₄-R) (Shaw et al., 2005; Keen-Rhinehart and Bartness, 2007) are responsible for acyl ghrelin-induced hyperphagic effects.

In addition to NPY/AgRP neurons in the arcuate nuclei, orexin, serotonin, and cannabinoid signaling pathways are actively participating in acyl ghrelin-stimulatory effects (Fig. 2). First, ghrelin-immunoreactive axonal terminals made direct synaptic contacts with orexin-producing neurons that made orexin very possible in the involvement of acyl ghrelin-induced feeding. Intracerebroventricular administration of acyl ghrelin induced c-fos expression, a marker of neuronal activation, in orexin-producing neurons in the lateral hypothalamus, whereas acyl ghrelin remained competent to induce c-fos expression in orexin-producing neurons even after pretreatment with anti-NPY immunoglobulin G (Toshinai et al., 2003). Pretreatment with anti-orexin-A and anti-orexin-B immunoglobulin G attenuated acyl ghrelin-induced feeding. In addition, acyl ghrelin-induced feeding was also suppressed in orexin knockout mice (Toshinai et al., 2003). These data reveal a novel hypothalamic pathway that links acyl ghrelin and orexin in the regulation of feeding behavior and energy homeostasis. Second, brain serotonin (5-hydroxytryptamine; 5-HT) systems also contribute to regulation of eating behavior and energy homeostasis. A selective serotonin-reuptake inhibitor decreased the effects of acyl ghrelin on food intake at the level of hippocampus (Carlini et al., 2007a), showing that the effects of acyl ghrelin on feeding in the hippocampus could depend on the availability of serotonin. 5-HT₂C receptors and 5-HT₁B receptors have been shown to mediate anorectic effects of 5-HT drugs. Twenty-four hours fasting increased the expression of hypothalamic 5-HT₂C receptor and 5-HT₁B receptor genes in association with increases in plasma acyl ghrelin levels compared with fed state in mice (Nonogaki et al., 2006). Treatment with serotonin reuptake inhibitor or 5-HT₂C receptor agonist significantly inhibited the increases in plasma active ghrelin levels without altering the expression of hypothalamic NPY, AgRP, and ghrelin genes, suggesting that there is a negative feedback system between brain 5-HT systems and plasma acyl ghrelin levels in energy homeostasis in mice (Nonogaki et al., 2006). Furthermore, fenfluramine, which stimulates the release of serotonin by disrupting vesicular storage of the neurotransmitter and reversing the serotonin transporter, inhibited marked food intake, which could be only partially reversed by intravenous acyl ghrelin or oral TJ-43, a spray-dried powder from herbal extracts of rikkunshito (Fujitsuuka et al., 2009), implying that the serotonin system acted on upstream regulation of ghrelin system on food intake. Third, acyl ghrelin was found to increase the endocannabinoid content of the hypothalamus in wild-type mice, and this effect was abolished by pretreatment with rimonabant, a cannabinoid receptor subtype 1 (CB₁-R) antagonist, whereas no effect was observed in CB₁-R-knockout animals (Kola et al., 2008). Intraperitoneal injection of acyl ghrelin did not induce an orexigenic effect in CB₁-R-knockout mice, whereas both the genetic lack of CB₁-R and the pharmacological blockade of CB₁-R inhibited the effect of peripheral acyl ghrelin on AMPK activity. Electrophysiological studies showed that acyl ghrelin can inhibit the excitatory inputs on the parvocellular neurons of the paraventricular nucleus and that this effect was abolished by administration of a CB₁-R antagonist, an inhibitor of the diacylglycerol lipase (the enzyme responsible for 2-arachidonoyl glycerol synthesis), or the presence of BAPTA (an intracellular calcium chelator), or the presence of BAPTA (an intracellular calcium chelator) (Kola et al., 2008). The evidence makes it clear that an intact cannabinoid signaling pathway is necessary for the stimulatory effects of acyl ghrelin on AMPK activity and food intake and for the inhibitory effect of acyl ghrelin on paraventricular neurons. However, early tolerance to the hypophagic effect of SR141716 (i.e., rimonabant) was reported to develop within 5 days; in contrast, however, its body weight-reducing action remained in rats, pointing out the important role of cannabinoid system in the regulation of body weight (Rigamonti et al., 2006). A study indicated that both cannabinoids and acyl ghrelin stimulated AMPK activity in the hypothalamus and the heart while inhibiting AMPK in liver and adipose tissue, demonstrating that AMPK is linked not only to the orexigenic effects of endocannabinoids and acyl ghrelin in the hypothalamus but also to their effects on the metabolism of peripheral tissues (Kola et al., 2005). To date, however, no information is available for interactions between CB₂-R and acyl ghrelin on food intake and body weight from PubMed search. Hence, studies using CB₂-R antagonist, such as AM-630, to investigate its actions with acyl ghrelin on food intake and body weight are demanded in the future.
III. Normal Physiology of Des-Acyl Ghrelin and Regulation of Its Expression and Interactions

Fasting induced the elevation of des-acyl ghrelin, the second ghrelin gene product, in mice (Kirchner et al., 2009), rats (Seoane et al., 2007a), and humans (Liu et al., 2008; Mondal et al., 2008), whereas feeding suppressed it (Seoane et al., 2007a; Liu et al., 2008; Mondal et al., 2008; Kirchner et al., 2009). Des-acyl ghrelin has been demonstrated to decrease food intake in mice (Asakawa et al., 2005) and rats (Chen et al., 2005a,b) centrally and peripherally in the fasted state. The action of des-acyl ghrelin was characterized by rapid onset (1 h) and short duration (2 h), but the suppressive effect was not durable (Chen et al., 2005b). In addition, the anorexigenic effects induced by des-acyl ghrelin in food-deprived rodents are mediated through distinct brain nuclei (compared with those by acyl ghrelin) by real-time RT-PCR and immunohistochemical studies. Intraperitoneal injection of des-acyl ghrelin induced mRNA expression of cocaine- and amphetamine-regulated transcript (CART) and urocortin 1, which are both anorexigenic neuropeptides to reduce food intake, in the mouse hypothalamus (Asakawa et al., 2005). Furthermore, intraperitoneal administration of des-acyl ghrelin elicited the amount of c-fos expression in the rat paraventricular nucleus neurons, presumably corticotropin-releasing factor (CRF) neurons (Chen et al., 2005b), without activating the nucleus of the solitary tract in the brainstem (Asakawa et al., 2005; Chen et al., 2005b) (Fig. 2). However, another two studies show discrepant results. Administration of des-acyl ghrelin did not affect feeding in fasted and freely fed mice (Neary et al., 2006; Toshinai et al., 2006), whereas central administration of des-acyl ghrelin increased light phase food intake in freely fed rats and mice by activating orexin-expressing neurons in the lateral hypothalamic area (Toshinai et al., 2006). It is very difficult to detect the effect of a satiation peptide during light phase under ad libitum feeding, most likely because of the satiation signals and the lack of the ability to further reduce the very low food intake during this phase. Des-acyl ghrelin has been reported to suppress dark-phase cumulative food intake and body weight gain in freely fed obese Zucker rats (Stengel et al., 2008) and to oppose acyl ghrelin-induced hyperphagic effects in freely fed lean rats (Inhoff et al., 2008), most likely to be mediated via central pathways. Moreover, repeated injection of des-acyl ghrelin for a period of 8 days induced a significant reduction of body weight gain that was not compensated or recovered in the 4 days after treatment (Stengel et al., 2008). A more recent study revealed that des-acyl ghrelin was secreted in a highly regulated manner in response to food deprivation in mice (Kirchner et al., 2009), supporting the idea that des-acyl ghrelin should play an as-yet undefined physiological role in feeding behavior rather than being an “innocent bystander.” These authors also suggested that des-acyl ghrelin might bind to an additional, unknown ghrelin receptor (Kirchner et al., 2009). Both peripheral and central injection of des-acyl ghrelin before acyl ghrelin consistently blocked the stimulatory effects on food intake induced by acyl ghrelin alone in the goldfish (Carassius auratus) (Matsuda et al., 2006), indicating that the interactions between acyl ghrelin and des-acyl ghrelin could be observed across species. Promisingly, des-acyl ghrelin was demonstrated to be involved in the regulation of human appetite (Muscari-tolli et al., 2007). Moreover, a decrease in body weight and fat pad mass weight accompanied moderately decreased linear growth in des-acyl ghrelin-overexpressing mice has been shown by two independent studies (Ariyasu et al., 2005; Asakawa et al., 2005), implying that, in contrast to acyl ghrelin, des-acyl ghrelin generates a negative energy balance (Asakawa et al., 2005). Taken together, the evidence indicates that des-acyl ghrelin is closely linked with ingestive behavior, metabolism, and body weight regulation, probably via counteracting the elevated level of endogenous acyl ghrelin under certain physiological situations and then dampening its biological effects, such as feeding and energy balance. Moreover, the anorexigenic effect of des-acyl ghrelin even appeared in rats without intact leptin signaling (Stengel et al., 2008). Therefore, des-acyl ghrelin alone or combined with leptin might offer new options of pharmacotherapy for the treatment of human obesity and metabolic syndrome. However, long-term impacts of des-acyl ghrelin on animal and human body weight regulation need to be established before the induction of pharmacologic interventions. Finally, des-acyl ghrelin did not affect water intake in chicks (Tachibana et al., 2006).

IV. Normal Physiology of Obestatin and Regulation of Its Expression and Interactions

The third ghrelin gene product, obestatin, a 23-amino acid peptide, was recently identified from rat stomach (Zhang et al., 2005). High levels of GPR39 mRNA were found abundantly in the amygdala, the hippocampus, and the auditory cortex but not in the hypothalamus (McKee et al., 1997; Jackson et al., 2006). Plasma obestatin levels were lower in obese subjects and those who had undergone gastrectomy (Huda et al., 2008). However, recent studies indicate that obestatin is not the endogenous cognate ligand for GPR39 (Lauwers et al., 2006; Holst et al., 2007; Chartrel et al., 2007), whereas a more recent study demonstrated that obestatin was a metabolic hormone capable of binding to GPR39 and, in turn, of regulating the diverse biological functions of gastrointestinal and adipose tissues (Zhang et al., 2008a). The plasma obestatin concentration did not change after a 450-kcal (Mondal et al., 2008) or even a 1550-kcal (Huda et al., 2008) meal in humans, identifying that obestatin secretion is not influenced by dietary nutrients. The effects of obestatin on food intake
remain controversial (Chen et al., 2009). Obestatin has been demonstrated to inhibit food intake in rodents (Zhang et al., 2005; Bresciani et al., 2006; Sibilia et al., 2006; Chartrel et al., 2007; Zizzari et al., 2007; Carlini et al., 2007; Green et al., 2007), whereas several research groups fail to show this anorexigenic effect (Seoane et al., 2006; Gourcerol et al., 2007; Nogueiras et al., 2007; Yamamoto et al., 2007; De Smet et al., 2007; Annemie et al., 2009; Kobelt et al., 2008; Mondal et al., 2008; Unniappan et al., 2008). Obestatin had no effect on body weight (Sibilia et al., 2006; Unniappan et al., 2008). However, the N-terminal obestatin (residues 1–13) was reported to reduce food intake and body weight, whereas the middle fragment (residues 6–18) did not affect food intake and body weight in mice (Nagaraj et al., 2008). Obestatin boluses increased the protein output and trypsin activity of pancreatic-biliary juice in anesthetized rats, whereas vagotomy abolished the effects of exogenous obestatin administration (Kapica et al., 2007). The data support that obestatin stimulates the secretion of pancreatic juice enzymes through a vagal pathway. Fasting induced elevation of plasma obestatin, whereas refeeding suppressed it, which adds another clue to the physiological functions of obestatin in regulating metabolism and energy homeostasis (Guo et al., 2008). However, peripheral obestatin failed to affect food intake in ghrelin-knockout mice (Depoortere et al., 2008). Acclimation of experimental animals, skills during experiments, and numbers of each group being inadequate to reach statistical power could all account for these discrepant results of obestatin on food intake. The cutting-edge knowledge of obestatin on food intake is reviewed by Chen et al. (2009). On the other hand, intracerebroventricular injection of obestatin inhibited water drinking in ad libitum-fed and -watered rats and in food- and water-deprived rats and inhibited angiotensin II-induced water drinking in rats provided free access to water and food (Samson et al., 2007), and the authors claimed that the effect of obestatin on food intake might be secondary to an initial action in inhibiting thirst phenomenon referred as “dehydration anorexia.” Dehydration anorexia could be one of the mechanisms through which to explain the discrepant results of obestatin on food intake. In an extended study, during a hypovolemic challenge, intracerebroventricular administration of obestatin significantly inhibited drinking of water but not saline (0.3 M NaCl) (Samson et al., 2008). Central obestatin also inhibited, in a dose-related fashion, dehydration-induced vasopressin secretion without affecting plasma oxytocin levels and vasopressin release induced by central angiotensin II (Samson et al., 2008), indicating that obestatin might be an important contributor to the physiologic regulation of fluid and electrolyte homeostasis by inhibiting the vasopressin system (Samson et al., 2007, 2008). However, another recent study failed to show an inhibitory effect of intracerebroventricular obestatin on water intake in mice (Annemie et al., 2009). Three recent studies also remind us to take major instability and impurity of obestatin peptides under biomedical investigations into account during interpretation for those discrepant data obtained in feeding behavior (Pan et al., 2006; De Spiegeleer et al., 2008; Vergote et al., 2008). Hence, in-depth exploration of obestatin on mammalian appetitive behavior, including microstructures of feeding and correction of situational physiological bias, should be further conducted (Chen et al., 2009).

V. Normal Physiology,Expression, and Regulation of Growth Hormone Secretagogue Receptor

The human full-length GHS-R1a cDNA encodes the predicted polypeptide of 366 amino acids with seven-transmembrane domains (TM), whereas GHS-R1b is predicted to encode a truncated polypeptide of 289 amino acids with only five TM. The GHS-R gene consists of two exons: the first exon encodes TM-1 to TM-5, and the second exon encodes TM-6 to TM-7. GHS-R1b is derived from the only first exon, encodes only five of the seven predicted TMs, and is thus a COOH-terminally truncated form of GHS-R1a and is pharmacologically inactive (Howard et al., 1996; Kojima and Kangawa, 2005). Acyl ghrelin acts on GHS-R1a, which belongs to family A, and, in turn, signals via a Gq/11α-subunit that results in the release of inositol trisphosphate and Ca2+ (Howard et al., 1996; Guan et al., 1997; Wetttscherek et al., 2005). GHS-R1b interacts with GHS-R1a and neurtensin receptor 1 to form heterodimer (Takahashi et al., 2006b). Emerging evidence suggests that the cloned GHS-R1a alone cannot be the responsible for all acyl ghrelin and GHS-mediated influence on food intake, gut motility, sleep, memory and behavior, glucose and lipid metabolism, cardiovascular performance, cell proliferation, immunological response, and reproduction. The cloned GHS-R1b isoform is apparently nonresponsive to ghrelin/GHS, despite demonstration of expression in neoplastic tissues responsive to ghrelin not expressing GHS-R1a; GHS-R1a homologs sensitive to acyl ghrelin are capable of interaction with GHS-R1b, forming heterodimeric species. [Heterogeneity, molecular identity, and transduction of the multiple levels of information, including the conservation across species for signaling molecules and receptors, of GHS-R1a and GHS-R1b are reviewed by Muccioli et al. (2007) (see Table 1).] The GHS-R1a is expressed very selectively in the brain centers related to regulation of energy homeostasis, such as hypothalamic nuclei, three components of the dorsal vagal complex (area postrema, nucleus of the solitary tract, and the dorsal motor nucleus of the vagus), the hippocampus, dopaminergic neurons in the ventral tegmental area and substantia nigra, parasympathetic preganglionic neurons, and in the dorsal and medial raphe nuclei, the pituitary, and the dentate gyrus (Gnanapavan et al., 2002; Kojima and Kangawa,
Obesity-prone rats fed a high-fat diet had increased body weight gain induced by high-fat diet. RT-PCR analysis revealed that GHS-R1a mRNA expression was detected in many human organs, including heart, lung, liver, kidney, pancreas, stomach, small and large intestine, adipose tissue, and immune cells (Gnanapavan et al., 2002; Sun et al., 2007), the highest levels occurring in pituitary, adrenal gland, and spinal cord (Sun et al., 2007; Ueberberg et al., 2009). These findings ascertain that acyl ghrelin has multiple functions in these central and peripheral tissues. By contrast, expression of GHS-R1b was found to be more widespread than that of GHS-R1a in all tissues investigated (Gnanapavan et al., 2002), raising the possibility that acyl ghrelin might function in a widespread fashion independent of GHS-R1a. The hypothalamic and hindbrain targets for acyl ghrelin are not well protected by the blood-brain barrier, and site-specific saturable transport of acyl ghrelin across the blood-brain barrier may provide additional access to GHS-R1a and deeper brain targets within the brain (Banks et al., 2002; Pan et al., 2006). GH-stimulating effect by peripheral acyl ghrelin was reported through direct central mechanisms in humans (le Roux et al., 2005a). On the other hand, the feeding-stimulating effects by peripheral acyl ghrelin could occur via indirect mechanisms; this idea is supported by the fact that peripheral acyl ghrelin had no effect on feeding in patients who had undergone vagotomy (le Roux et al., 2005a) and in rodents with surgical or chemical vagotomy (Asakawa et al., 2001b; Date et al., 2002; Chen et al., 2005b) or lesions in caudal brain stem (Date et al., 2002; Gilg and Lutz, 2006). However, contradictory opinion exists (Arnold et al., 2006). In addition, the hypothalamus produced small quantities of acyl and des-acyl ghrelin by itself (Cowley et al., 2003; Mondal et al., 2005; Sato et al., 2005), which would act locally as neuropeptides modulating neurons for energy balance.

Consistent with the notion that acyl ghrelin expression is closely modulated by food intake, GHS-R1a is regulated according to feeding status. Acyl ghrelin mRNA levels in the stomach, and GHS-R1a mRNA levels in the hypothalamus and pituitary gland, increased after 48-h fasting in rats, whereas refeeding decreased them (Kim et al., 2003b). Body weight loss by sleeve gastrectomy in obese rats induced by high-fat diet was accompanied decrease of plasma ghrelin concentration and increased expression of GHS-R1a in the hypothalamus compared with sham controls (Wang and Liu, 2009). The increased GHS-R1a in the hypothalamus and/or pituitary gland could contribute to augment the actions of acyl ghrelin in these organs and may be considered a physiologic mechanism to increase appetite and adiposity in energy-deficient state (Kim et al., 2003b; Wang and Liu, 2009). Intracerebroventricular leptin decreased GHS-R1a mRNA in the arcuate nucleus accompanied inhibition of food intake and body weight gain, whereas intracerebroventricular acyl ghrelin increased GHS-R1a mRNA in the arcuate nucleus in rats (Nogueiras et al., 2004). During fasting (with high levels of plasma acyl ghrelin and low levels of plasma leptin) and in obese Zucker rats (insensitive to leptin), increased GHS-R1a mRNA was detected in the arcuate nucleus (Nogueiras et al., 2004), indicating that satiation and hunger signals are both involved in the regulation of GHS-R1a expression in the brain in addition to feeding. Direct morphological evidence identified that GHS-R1a was produced in the stomach-projected afferent neurons of the nodose ganglion in rats, suggesting that ghrelin signals from the stomach are transmitted to the brain via vagal afferent nerves (Sakata et al., 2003). Obesity-prone rats fed a high-fat diet had increased body weight, increased adiposity, and increased mRNA expression of GHS-R1a and CB1-R in the nodose ganglion compared with low-fat diet-fed control rats or high-fat diet-induced obesity-resistant rats (Paulino et al., 2009), demonstrating that shifts in the balance between orexigenic and anorexigenic signals within the vagal afferent pathway might influence food intake and body weight gain induced by high-fat diet.

VI. Normal Physiology, Expression, and Regulation of Ghrelin O-acyltransferase

The acylated modification of ghrelin with an eight-carbon fatty acid, octanoate, at serine-3 is crucial for the physiological effects of acyl ghrelin, such as GH release, food eating, adiposity, and insulin secretion. GOAT, a polytopic membrane-bound enzyme that attaches octanoate to serine-3 of ghrelin, was recently identified and character-
ized (Yang et al., 2008a; Gutierrez et al., 2008). Analysis of the mouse genome revealed that GOAT belongs to a family of 16 hydrophobic membrane-bound acyltransferases that includes Porcupine, which attaches long-chain fatty acids to Wnt proteins (Yang et al., 2008a). GOAT is a conserved orphan membrane-bound O-acyl transferase (MBOAT) that specifically octanoylates serine-3 of the ghrelin peptide. GOAT is the only member of this family that octanoylates ghrelin when coexpressed in cultured endocrine cell lines with prepro-ghrelin (Yang et al., 2008a). GOAT activity requires catalytic asparagine and histidine residues that are conserved in this family. GOAT is the only member of the membrane-bound O-acyl transferase family, the expression of which is highly enriched within gastric ghrelin cells and the whole body distribution of which colocalizes with that of ghrelin (Sakata et al., 2009). The occurrence of ghrelin and GOAT in stomach and pancreas tissues demonstrates the relevance of GOAT in the acylation of ghrelin and further implicates acyl ghrelin in pancreatic function in addition to its gastric function (Gutierrez et al., 2008).

GOAT was subjected to end-product inhibition, and this inhibition was better achieved with substrates having the octanoyl group attached through an amide linkage rather than the corresponding ester (Yang et al., 2008b). Unexpectedly, although the main active form of ghrelin is modified by n-octanoic acid, a recent enzymological analysis showed that GOAT had a strong preference for n-hexanoyl-CoA over n-octanoyl-CoA as an acyl donor (Ohgusu et al., 2009). However, the concentration of n-hexanoyl ghrelin in the mouse stomach is very low compared with that of n-octanoyl ghrelin (Ohgusu et al., 2009), raising the presumption that different concentrations between n-hexanoyl-CoA and n-octanoyl-CoA in the stomach may affect the production and concentration of various acyl-modified ghrelin. From PubMed search, there is no information regarding the biological actions of hexanoyl-ghrelin. These insights may facilitate the future design of useful inhibitors of GOAT.

Because nonacylated peptide does not stimulate appetite, it is intriguing to determine whether GOAT activity modulates in feeding regulation. Chronic undernutrition markedly increased the expression of GOAT mRNA levels in stomach mucosae, offer a mechanistic explanation of the increased acyl ghrelin levels observed in patients with severe malnutrition (González et al., 2008). Using absorbable medium-chain fatty acid, GOAT-ghrelin system could act as a nutrient sensor to tell the brain that high caloric food is available, leading to fat storage, nutrient partitioning, and growth signals (Kirchner et al., 2009). A recent study indicated that meals inhibited secretion of acyl and des-acyl ghrelin, yet long-term fasting inhibited acylation but not total secretion, suggesting that acylation might be regulated independently of secretion by nutrient availability in the gut or by esterases that cleave the acyl group (Liu et al., 2008).

VII. Pathophysiology of Ghrelin Gene Products in Feeding and Body Weight Regulation

A. Relationships between Plasma Levels of Ghrelin Gene Products and Body Weight Homeostasis

Circulating ghrelin concentrations significantly correlate with human body mass index and body fatness and are low in obese persons. The negative association between ghrelin secretion and body weight is emphasized by evidence that weight decrease augments circulating ghrelin levels in anorexia and weight increase reduces circulating ghrelin levels in obesity. Plasma ghrelin levels increase in energy deficient conditions (see section XI). Moreover, the increase in ghrelin level is closely coupled with markedly elevated expression of GHS-R1a in the hypothalamus in fasting or long-term food restriction (Kim et al., 2003b; Nogueiras et al., 2004; Kurose et al., 2005), reflecting an enhanced feeding feedback for ghrelin-induced stimulation of appetite during weight loss. Conversely, circulating ghrelin levels decrease in energy excessive conditions (also see Section XI). Prader-Willi syndrome, a “hereditary hyperghrelinemia,” is an exception to have increased body weight and plasma ghrelin concentrations. Therefore, ghrelin/GHS-R1a system contributes to the adaptive metabolic mechanisms to such alterations and feedback signaling cascade among human nutrient intake and the central nervous system, and actively participates in the regulation of short- and long-term mammalian energy balance and body weight.

B. Acyl Ghrelin in Feeding and Body Weight Regulation

Long-term central administration of rat acyl ghrelin significantly increased food intake and body weight (Kamgeai et al., 2001). Furthermore, the feeding-eliciting action of exogenous acyl ghrelin was not diminished by a long-term hyperghrelinemia in transgenic mice overexpressing human ghrelin gene, indicating that the food ingestive pathway of the GHS-R1a was not susceptible to “desensitization” (Wei et al., 2006). In contrast, the epididymal fat pad growth and the GH responses to exogenous acyl ghrelin were blunted in ghrelin transgenic mice with chronic hyperghrelinemia (Wei et al., 2006). Short-term exogenous administration of high-dose acyl ghrelin stimulated energy intake in obese and in lean subjects, whereas low-dose acyl ghrelin increased food intake only in obese people (Druce et al., 2005). Administration of acyl ghrelin provoked palatability only in the obese group, but not in the lean group, whereas the GH-releasing effect was attenuated in obese subjects compared with lean subjects (Druce et al., 2005). Collectively, the evidence revealed that the feeding response to acyl ghrelin was maintained in obesity. Obese people were sensitive to appetite-stimulating effects of acyl ghrelin, and the orexigenic ability was independent of GH release in obesity. This highlights the idea that inhibition of circulating acyl ghrelin may be a
useful therapeutic target in the treatment of obesity. However, an animal study showed that an increased fat mass per se did not exert an inhibitory effect on acyl ghrelin homeostasis during ingestion of a 5-week high-fat diet in rats (Qi et al., 2008), presuming that endogenous signal for activation of ingestive behavior could still remain intact despite excess stored calories in high-fat-fed rats. In addition, rats fed with 5 weeks on diets rich in sucrose and/or fat showed elevated expression of leptin mRNA in the stomach and serum leptin concentration in response to sucrose-rich rather than fat-rich diets, linking leptin with sucrose metabolism and suppressed expression of ghrelin in the stomach and serum total ghrelin level by all palatable diets, including sucrose and fat (Lindqvist et al., 2005). Rats fed on palatable diets overeat; increased body weight and adiposity despite raising satiation peptide (leptin) and lowering hunger peptide (ghrelin). These results imply that leptin/ghrelin systems were blunted, and only the above endogenously responsive hormones are insufficient to control appetite, body weight gain, and adiposity in palatable food diet.

C. Interactions between Ghrelin Gene Products and the Blood-Brain Barrier

The blood-brain barrier prevents the unrestricted exchange of substances between the central nervous system and the blood and also conveys information between the central nervous system and the gastrointestinal tract through several mechanisms. Saturable systems transported human acyl ghrelin from brain to blood and from blood to brain, whereas mouse acyl ghrelin was a substrate for the brain-to-blood transporter but not for the blood-to-brain transporter (Banks et al., 2002). The second ghrelin gene product, des-acyl ghrelin, entered the brain by nonsaturable transmembrane diffusion and was sequestered once within the central nervous system (Banks et al., 2002). In contrast, the third ghrelin gene product, obestatin, lacked specific binding and endocytosis, and did not cross the blood-brain barrier. Small amounts of internalized obestatin showed rapid intracellular degradation before the radioactivity was released by exocytosis (Pan et al., 2006). These pharmacokinetic experiments illustrated distinctive physiological interactions of three ghrelin gene products with the central nervous system (Fig. 3). Moreover, serum factors and physiological states affect the ghrelin gene products across the blood-brain barrier. First, obesity and old age lost the ability to transport intravenous human acyl ghrelin across the blood-brain barrier, resulting in an inverse relationship between body weight and acyl ghrelin blood-brain barrier permeability (Banks et al., 2008). Second, serum triglycerides promoted transport of intravenous acyl ghrelin across the blood-brain barrier (Banks et al., 2008). Third, fasting tended to enhance acyl ghrelin transport across the blood-brain barrier (Banks et al., 2008). Collectively, high fat diet and starvation would augment orexigenic effects of acyl ghrelin on the central nervous system by increasing its crossing the blood-brain barrier, whereas obesity and old age would ameliorate the actions of acyl ghrelin on the brain by decreasing its crossing the blood-brain barrier (Fig. 3). Emerging evidence reveals that the orexigenic effects by peripheral acyl ghrelin could occur via indirect mechanisms and be dependent on the vagal afferent pathway (Asakawa et al., 2001b; Date et al., 2002; Chen et al., 2005b; le Roux et al., 2005a; Gilg and Lutz, 2006), whereas GH release induced by peripheral acyl ghrelin could occur via direct mechanism (le Roux et al., 2005a).

**Fig. 3.** Differential transportation of mouse acyl ghrelin, mouse des-acyl ghrelin, human acyl ghrelin, and mouse obestatin across the blood-brain barrier, which regulates communications between the gut and the brain. Obesity, old age, serum triglyceride, and fasting affect acyl ghrelin across the blood-brain barrier.
D. Interactions between Acyl Ghrelin and Helicobacter pylori on Feeding

Chronic noninvasive bacterial infection causes altered feeding behavior. Chronic Helicobacter pylori infection in mice caused increased mononuclear cell infiltration in gastric corpus, larger gastric area, delayed gastric emptying, elevated plasma acyl ghrelin and cholecystokinin levels, and lowered pro-opiomelanocortin (POMC) mRNA expression in the arcuate nucleus; all returned to control values after eradication of H. pylori (Bercik et al., 2009). However, altered feeding behavior, such as decreased amount of food per bout and increased frequency of bouts, persisted after eradication of H. pylori, which was paralleled by persistently elevated gastric CD3+ T cells in the stomach and increased expression of TNF-α mRNA in the brain (Bercik et al., 2009), implying that central nervous system changes might be slow to resolve after chronic infection and persist after eradication of the triggering gastrointestinal infection, supporting a role for altered gut-brain pathways in persistent abnormal feeding behavior after postinfection gut dysfunction.

E. Total Acyl Ghrelin and Burn Injury

Burn injury is a common clinical problem and induces persistent hypermetabolism and muscle wasting. Total plasma ghrelin was reduced 1 day after burn in rats (Balasubramaniam et al., 2006). Intraperitoneal injection of acyl ghrelin greatly stimulated 2-h food intake in rats on five separate days after burn, whereas on day 15 after the burn, plasma growth hormone levels were significantly lower than in control rats, and this was restored to normal levels by exogenous acyl ghrelin supplement (Balasubramaniam et al., 2006). These observations suggest that ghrelin retains its ability to favorably modulate both the peripheral anabolic and central orexigenic signals, even after thermal injury, despite ongoing changes from prolonged and profound hypermetabolism (Balasubramaniam et al., 2006). Long-term treatment with acyl ghrelin may attenuate endocrine- and feeding-related dysfunctions in patients with burn injury in the future.

F. Growth Hormone Secretagogue Receptor Agonist and Postoperative Anorexia-Cachexia

Postoperative ileus is an impairment of coordinated gastrointestinal motility that develops as a consequence of abdominal surgery. The abnormal gastrointestinal motility often leads to abdominal bloating, vomiting, lack of defecation, and poor appetite after surgery. Repetitive intravenous administrations of ipamorelin, a novel synthetic GHS-R1a agonist, significantly increased laparotomy and intestinal manipulation-induced reduction of food intake and body weight in rats, in addition to its effect on cumulative fecal pellet output (Venkova et al., 2009), implying that postsurgical mul-

tiple intravenous bolus infusion of ipamorelin might ameliorate the symptoms of anorexia-cachexia in patients with postoperative ileus.

G. Total Acyl Ghrelin and Functional Dyspepsia

Functional dyspepsia is a common gastrointestinal disorder that is defined by the Rome III criteria. Plasma total ghrelin in patients with functional dyspepsia could be lower (Takamori et al., 2007; Lee et al., 2009), similar (Shinomiya et al., 2005; Plichiewicz et al., 2008), or higher (Nishizawa et al., 2006) compared with healthy subjects. Plasma acyl ghrelin levels correlated with “subjective symptom score” in female patients with functional dyspepsia (Shinomiya et al., 2005), whereas plasma acyl and total ghrelin levels correlated with “ingestive score” in another group of patients with functional dyspepsia (Nishizawa et al., 2006). Repeated intravenous administration of acyl ghrelin tended to increase daily food intake and significantly induced hunger sensation in patients with functional dyspepsia (Akamizu et al., 2008).

H. Acyl Ghrelin, Reward Feeding, and Related Body Weight Regulation

In addition to expression in the hypothalamus, GHS-R1a is expressed in brain sites other than the hypothalamus, such as the ventral tegmental area, a primary node of the mesolimbic reward neuropathway, which sends dopaminergic projections to the nucleus accumbens (Kelley and Berridge, 2002), suggesting central effects of ghrelin on energy balance and other functions, which may recruit extrahypothalamic circuits. Emerging evidence reveals that besides acting through visceral vagal afferent associated gut-brain axis and blood-mediated signals directly on the level of the hypothalamus (i.e., an energy homeostatic process), ghrelin gene products are also deeply involved in modulating reward and motivation in enhancing the hedonic and incentive responding to food-related cues (Wellman et al., 2005; Malik et al., 2008a) or context (Smith et al., 2010). For instance, acyl ghrelin was reported to alter the appetitive and consummatory response to learned cues associated with food in mice and rats in nonhomeostatic brain feeding nuclei (Johnson et al., 2009). Microinjection of acyl ghrelin into the ventral tegmental area, the key structures of the mesolimbic dopamine system, elicited robust feeding behavior, whereas its microinjection into the nucleus accumbens induced a moderate eating pattern in rats (Naleid et al., 2005; Abizaid et al., 2006). Intraperitoneal administration of acyl ghrelin induced locomotor stimulation, conditioned place preference, and accumbal dopamine overflow in mice (Jerlhag, 2008). Phasic dopamine release is crucial in reward behavior (Hajnal et al., 2009). A microdialysis study showed that subcutaneous administration of acyl ghrelin in rats increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens, the main...
projecting structure of the mesolimbic dopamine system (Quarta et al., 2009). These findings suggest that systemic acyl ghrelin may regulate the valence of reinforcers such as food and drugs of abuse by interfering with mesolimbic dopamine activity. Blockade of dopamine β-hydroxylase in the hindbrain abolished acyl ghrelin-induced feeding (Date et al., 2006), which implies that the action of acyl ghrelin action could be noradrenergic neuron-dependent and could be involved in rewarding mechanisms. Using functional magnetic resonance imaging techniques, the neuronal response to food pictures increased in the amygdala, orbitofrontal cortex, anterior insula, and striatum regions of the brain after intravenous administration of acyl ghrelin in healthy human volunteers, implicating acyl ghrelin in encoding the incentive value of food cues (Malik et al., 2008b). In addition, the actions of acyl ghrelin in the amygdala and orbitofrontal cortex were correlated with self-rated hunger gradings (Malik et al., 2008b). A recent study demonstrated that alcohol-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference were abolished in models of suppressed central acyl ghrelin signaling; GHS-R1a was either knocked out or knocked down, pointing to a requirement for central acyl ghrelin signaling for alcohol reward (Jerlhag et al., 2009). The preprandial rise in plasma acyl ghrelin may increase the incentive value for motivated behaviors such as food seeking, and ghrelin signaling constitutes a potential target for the treatment of compulsive overeating or alcohol addiction (Jerlhag, 2008; Jerlhag et al., 2009). Moreover, fasting plasma acyl ghrelin levels were higher in persons with chronic alcoholism during a period of abstinence than in control subjects (Kim et al., 2005a). Besides, a positive correlation was observed between acyl ghrelin levels and the duration of abstinence, whereas daily alcohol intake before abstinence was inversely related to acyl ghrelin levels. Hence, these findings suggest that acyl ghrelin plays a role in the pathogenesis of “alcohol dependence,” particularly during the abstinence period, in persons with chronic alcoholism (Kim et al., 2005a). Emerging evidence from rodents to humans indicates the inextricably biological roles of acyl ghrelin in metabolism and reward linked to regulation of eating behavior. The rapid growing obesity epidemic may be partially mediated by an increase in the exposure to cues for food in our modern society. Biologic pathways regulating appetite and craving are often overlapped and interacted (Kalra and Kalra, 2004). Appetitive behavior is influenced by both strong regulatory drives and taste-hedonics, whereas cognitive-rewarding-social-emotional mechanisms can often override homeostatic control systems by various palatable food stimuli; therefore, targeting ghrelin gene products, via either responsible homeostatic or reward (nonhomeostatic) neuronal circuits, or both, holds the promise of the induction of satiation, control of food intake, and, eventually, diminished body energy stores, normalization of body weight regulation under obesogenic environments, and combat against alcohol or drug craving during withdrawal in humans in this modern society.

VIII. Normal Physiology and Pathophysiology of Ghrelin Gene Products in Feeding-Associated Gastrointestinal Motility

Ghrelin gene products actively participate in the regulation of feeding-associated gastrointestinal motility. Results from electrophysiologic studies provide us the mechanisms by which acyl ghrelin diversely influences cellular excitability and neuronal circuitry in the hindbrain, contributing its biological actions on feeding and gastric motility (Wang et al., 2008). Circulating acyl ghrelin levels were fluctuating and their peak was highly associated with gastric migrating motor complex cycle (Ariga et al., 2007). Endogenous acyl ghrelin released from gastric X/A cells mediated gastric phase III-like contractions via vagal-dependent pathways in mice (Zheng et al., 2009a) and in rats (Ariga et al., 2007; Taniguchi et al., 2008), whereas serotonin released from enterochromaffin cells of duodenal mucosa mediated intestinal phase III-like contractions via 5-HT4 receptors located on intrinsic primary afferent neurons in rats (Taniguchi et al., 2008). Intravenous exogenous acyl ghrelin increased motility index in the antrum in dogs (Yin and Chen, 2006). Intracerebroventricular and intravenous exogenous acyl ghrelin increased motility index in the antrum and induced in the duodenum a motor activity pattern resembling that after fasting in conscious fed rats (Fujino et al., 2003) (see Table 2). The effects of intracerebroventricular and intravenous injected acyl

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Drug Administration</th>
<th>Status</th>
<th>MI Frequency of Phase III-Like Contractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat acyl ghrelin</td>
<td>i.v. and i.c.v.</td>
<td>Acutely fed</td>
<td>↑↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fasted</td>
<td>↑↑</td>
</tr>
<tr>
<td>Rat des-acyl ghrelin</td>
<td>i.v. and i.c.v.</td>
<td>Acutely fed</td>
<td>↑↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fasted</td>
<td>↑↑</td>
</tr>
<tr>
<td>Rat obestatin</td>
<td>i.v.</td>
<td>Acutely fed</td>
<td>↑↑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fasted</td>
<td>↑↑</td>
</tr>
</tbody>
</table>

i.v., intravenous; i.c.v., intracerebroventricular; MI, motility index; N.A., not applicable.
ghrelin were blocked by GHS-R antagonist given via the same route and also were blocked by immunoneutralization of NPY in the brain. Intravenous infusion of acyl ghrelin induced in the antrum and duodenum in vagotomized rats a motor pattern similar to that found after fasting, whereas intracerebroventricular injection of acyl ghrelin failed to affect motor activity, suggesting that once the brain mechanism was eliminated by truncal vagotomy, acyl ghrelin might primarily regulate fasting motor activity through GHS-R1a on the stomach and duodenum (Fujino et al., 2003). Furthermore, intraperitoneal acyl ghrelin injection elicited c-fos immunoreactivity in the nucleus of the solitary tract and arcuate nucleus (Chen et al., 2005b), revealing that brain NPY neurons (Fujino et al., 2003), probably via Y$_2$ or Y$_4$ receptors (Fujimiya et al., 2008), and vagal afferent pathways, were involved in acyl ghrelin-induced stimulation of a fasting gastrointestinal motor activity pattern (see Table 3). Acyl ghrelin dose-dependently shortened the migrating motor complex cycle length in the duodenum and jejunum through intrinsic cholinergic neurons in awake rats (Edholm et al., 2004). In addition, intraperitoneal exogenous acyl ghrelin administration enhanced antropyloric coordination, which could contribute to accelerated solid gastric emptying induced by acyl ghrelin in rats (Ariga et al., 2008c). Acyl ghrelin-induced gastric phase III-like contractions were also found via vagal cholinergic pathways in mice (Zheng et al., 2009a). A recent study demonstrated that fenfluramine decreased plasma acyl ghrelin concentration and suppressed gastric and duodenal phase III-like contractions and that this could be reversed by intravenous acyl ghrelin or oral TJ-43 (Fujitsu et al., 2009), also implying that the ghrelin system acted at the down-stream regulation of serotonin system on gastroduodenal motility. Intravenous infusion of acyl ghrelin provoked a premature gastric phase III migrating motor complex in healthy human volunteers that was not mediated through release of motilin (Tack et al., 2006), revealing that the migrating motor complex-inducing ability by acyl ghrelin is present across species. The stimulation of acyl ghrelin on human gastric phase III migrating motor complex was accompanied by increased plasma levels of pancreatic polypeptide and prolonged increased tone of the proximal stomach (Tack et al., 2006).

Exogenous intravenous acyl ghrelin administration stimulated gastric motility (Masuda et al., 2000), gastric myoelectrical activity (in terms of increasing dominant frequency and normal slow wave, and decreasing dominant power), and enhanced liquid gastric emptying (Tümer et al., 2008) in rats. The stimulatory effects on gastric myoelectrical activity and liquid gastric emptying were not fully blocked by subcutaneous pretreatment with atropine sulfate, suggesting that the gastroprokinetic actions of acyl ghrelin are mediated not only by the vagal cholinergic muscarinic pathway but also by intrinsic local pathways via action on as-yet undefined receptors (speculated) and signaling noncholinergic excitatory neurotransmitters in the enteric nervous system in gastric smooth muscle (Tümer et al., 2008). However, intravenous injection of canine acyl ghrelin stimulated GH release in a dose-dependent manner, but did not stimulate the motor activity of the digestive tract in either the fasted or the fed state in dogs (Ohno et al., 2006). Moreover, intravenous high-dose canine acyl ghrelin significantly reduced the motility index in the gastric body in the fasted state. Acyl ghrelin did not accelerate gastric emptying in dogs, either (Ohno et al., 2006). These results differ from previous reports dealing with rodents and remind us to be cautious during interpretation of experimental results obtained in research with larger animals such as dogs.

Central and peripheral application of acyl ghrelin enhanced nutrient solid and non-nutrient semiliquid gastric emptying in mice (Asakawa et al., 2001b; Dornonville de la Cour et al., 2004; Kitazawa et al., 2005; De Winter et al., 2004) and in rats (Trudel et al., 2002; Fukuda et al., 2004; Chen et al., 2005a, 2008b; Depoortere et al., 2005; Levin et al., 2005). Central and peripheral administered acyl ghrelin also stimulated small intestinal transit in rats (Trudel et al., 2002; Fukuda et al., 2004; Chen et al., 2005, 2008b). The ghrelin analog RC-1139 (Poirras et al., 2005) promoted non-nutrient semiliquid gastric emptying in mice (Dornonville de la Cour et al., 2004). Intravenous or subcutaneous administration of acyl ghrelin elicited hunger (in terms of appetite score), accelerated solid meal gastric emptying in normal-weight healthy volunteers and normal-weight patients with GH deficiency (Levin et al., 2006), and increased energy intake and enhanced the perceived palatability of the food offered (pleasantness, in terms of palatability score) in leaner human volunteers and obese subjects (Druce et al., 2005, 2006). The authors also showed that the gastric emptying-stimulating ability of intravenous acyl ghrelin was not mediated via GH and motilin (Levin et al., 2006). The effects of acyl ghrelin on gastric emptying and small intestinal transit are reviewed by Chen et al. (2008c). Taken together, these

---

**TABLE 3**

Differential activation of corresponding hypothalamic neurons, brain receptors, and neuroendocrine pathways induced by peripheral effects of ghrelin gene products

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Hypothalamic Neuron Activated</th>
<th>Brain Receptors Mediated</th>
<th>Vagal Afferent Dependence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat acyl ghrelin</td>
<td>NPY</td>
<td>Y$_2$ and Y$_4$ receptors</td>
<td>Yes</td>
</tr>
<tr>
<td>Rat des-acyl ghrelin</td>
<td>CRF</td>
<td>CRF$_{1a}$-R</td>
<td>No</td>
</tr>
<tr>
<td>Rat obestatin</td>
<td>CRF and urocortin 2</td>
<td>CRF$<em>{1a}$-R and CRF$</em>{2a}$-R</td>
<td>Partially</td>
</tr>
</tbody>
</table>
couple acyl ghrelin with orexigenic, gastropokinetic, and hedonic-rewarding effects. Solid meal gastric emptying in children with Prader-Willi syndrome was delayed (Choe et al., 2005) and non-nutrient liquid gastric emptying in adults with Prader-Willi syndrome was normal (Hoybye et al., 2007), despite higher acyl ghrelin levels, suggesting that the voracious appetite associated with Prader-Willi syndrome could be something other than the gastric emptying mechanism.

Regarding colonic motility, intracerebroventricular and intraperitoneal injection of acyl ghrelin decreased colonic transit time in conscious fed rats, which was blocked by pretreatment with intracerebroventricular Y1 receptor antagonist, but not Y2 receptor antagonist (Tebbe et al., 2005b). Furthermore, acyl ghrelin bilaterally microinjected into the paraventricular nucleus induced a significant stimulation of colonic propulsion, resulting in the shortening of colonic transit time. The enhanced colonic motility induced by microinjection of acyl ghrelin into the paraventricular nucleus was abolished by pretreatment with the nonselective CRF-R antagonist and Y1 receptor antagonist inside the paraventricular nucleus, but not by the selective CRF2-R antagonist (Tebbe et al., 2005a). Collectively, acyl ghrelin could act in the central nervous system, including inside the paraventricular nucleus, to modulate colonic motor function by using Y1 receptor and CRF1-R dependent mechanisms (Fig. 4). In addition, intrathecal application of CP-464709-18 (Carpeno et al., 2002; Atcha et al., 2009), a synthetic GHS-R1a agonist, at L6-S1, but not application at pontomedullary levels or to the thoracic spinal cord, elicited propulsive contractions. The stimulation evoked by intravenous CP-464709-18 was prevented if the pelvic nerve outflows were severed, but not if the spinal cord was cut rostral to the defecation center at L6–S3, and was also blocked by hexamethonium (Shimizu et al., 2006). The findings also suggested that activation of GHS-R1a in the lumbosacral spinal cord, via the pelvic nerves, triggered coordinated propulsive contractions that emptied the colorectum. Oral administration of a centrally acting GHS-R1a agonist, GSK894281, to conscious rats also triggered defecation (Shafton et al., 2009). Therefore, oral administration of GHS-R1a agonists that enter the central nervous system could possibly be used to relieve acute cases of constipation or to clear the bowel before colonoscopy.

Conversely, intracerebroventricular and intravenous injection of des-acyl ghrelin decreased gastric phase III-like contractions and disrupted motor activity pattern after fasting in the antrum in conscious rats (Chen et al., 2005b). Intracerebroventricular and intravenous effects of des-acyl ghrelin on stomach motility after fasting were blocked by truncal vagotomy, whereas disruptive effects by intravenous des-acyl ghrelin on stomach motility after fasting were not altered by capsaicin treatment. These results, together with elicitation of c-fos immunoreactivity in the arcuate nucleus and paraventricular nucleus (Asakawa et al., 2005; Chen et al., 2005b) without activation of that in nucleus of the solitary tract (Chen et al., 2005b) by intraperitoneal des-acyl ghrelin administration, suggest that the actions of peripheral des-acyl ghrelin could cross the blood-brain barrier and might occur through vagal efferent signaling but independent of vagal afferent pathways. Pretreatment with nonselective CRF-R antagonist and the selective CRF2-R antagonist, but not CRF1-R antagonist, blocked the disruptive effects of des-acyl ghrelin on motor activity after fasting in the antrum, indicating that CRF2-R in the brain mediated this action (Chen et al., 2005b). Intracerebroventricular and intravenous effects of des-acyl ghrelin consistently suppressed solid gastric emptying in mice (Asakawa et al., 2005), whereas intracisternal injection of des-acyl ghrelin inhibited semifluid gastric emptying in rats (Chen et al., 2005a). The disruptive effects by des-acyl ghrelin on the gastric motility after fasting in the antrum through activation of CART and urocortin 1, then subsequently signaling via CRF2-R in the brain, could contribute to the delayed semifluid gastric emptying induced by des-acyl ghrelin in rodents. However, subcutaneous injection of des-acyl ghrelin did not antagonize cholecystokinin-induced inhibition of non-nutrient semifluid gastric emptying in conscious mice (Dornonville de la Cour et al., 2004).

Similar to ingestive behavior, the effects of obestatin on the upper gastrointestinal motility are still debatable. Using a freely moving conscious rat model, intravenous obestatin decreased motility index in the antrum and inhibited phase III-like contractions in the duodenum (Ataka et al., 2008). Immunohistochemical analysis revealed that intravenous obestatin elicited c-fos immunoreactivity in the arcuate nucleus, paraventricular nucleus, and nucleus of the solitary tract and activated CRF- and urocortin 2-containing neurons in the brain (Ataka et al., 2008). The effects of peripheral obestatin
on the duodenum, but not on the antrum, were abolished by perivagal capsaicin treatment, whereas intracerebroventricular injection of the selective CRF<sub>R</sub>-R and CRF<sub>2-R</sub> antagonists blocked the suppressive effects of intravenous obestatin on the antrum and duodenum. Collectively, these results imply that the inhibitory actions of peripheral obestatin on fed gastroduodenal motility required brain CRF<sub>R</sub>-R and CRF<sub>2-R</sub>-R, and vagal afferent pathways might be partially involved (Ataka et al., 2008; Fujimiya et al., 2008) (see Tables 2 and 3). In contrast, intraperitoneal obestatin did not affect gastric emptying parameters and did not inhibit the prokinetic effects of acyl ghrelin (De Smet et al., 2007). Mouse and rat intestinal and fundic smooth muscle strips did not respond to obestatin either in the absence or in the presence of electrical field stimulation (De Smet et al., 2007). Lower dose of obestatin (0.1–1 nM) reduced the ability of acyl ghrelin to facilitate electrical field stimulation-evoked contractions of the stomach, but higher concentrations (10–1000 nM) only tended to reduce the response to acyl ghrelin but changes were not statistically significant (Bassil et al., 2007a). Intravenous acyl ghrelin increased liquid gastric emptying and reduced migrating motor complex cycle time, whereas intravenous infusion of obestatin had no effects (Bassil et al., 2007a). Intravenous obestatin failed to prevent intravenous acyl ghrelin-induced shortening of cycle time in terms of duodenal phase III-like contractions (Ataka et al., 2008) and small intestinal migrating motor complex (Bassil et al., 2007a), as well as the increase of motility index in the antrum (Ataka et al., 2008) in rats. In addition, peripheral obestatin failed to affect gastric emptying in ghrelin-knockout mice (Depoortere et al., 2008). A novel in vivo animal model simultaneously measuring colonic motility and secretion showed that intravenous obestatin administration has no effect on colonic motor and secretory functions in rats, whereas human/rat CRF had stimulatory effects in conscious fed rats (Chen et al., 2008a) (Fig. 4). Taking these data together, obestatin has little ability to modulate gastric emptying, and seems not to be a physiological opponent to counteract acyl ghrelin to modify rodent gastrointestinal motility.

A novel relationship of ingestive behavior and gastric motor function was recently proposed. Fixed feeding increased plasma acyl ghrelin levels, potentiated interdigestive gastric contractions, and accelerated solid gastric emptying (Ariga et al., 2008a), implying that irregular eating habits might impair gastric migrating motor complex and induce postprandial symptoms in humans.

Mice chronically infected with H. pylori manifested with higher plasma acyl ghrelin level and delayed gastric emptying rate, whereas eradication of H. pylori restored these two abnormalities but not feeding behavior, implying that central nervous system changes might be slow to recover and persist after eradication of the triggering gut infection after chronic infection.

Delayed gastrointestinal transit is a common problem in patients with severe burn. Severe cutaneous burn injury significantly delayed non-nutrient liquid gastric emptying, intestinal transit, and colonic transit compared with sham injury, whereas intraperitoneal application of acyl ghrelin normalized both non-nutrient liquid gastric emptying and intestinal transit, but not the colonic transit in rats (Sallam et al., 2007). Subcutaneous atropine blocked the prokinetic effects of acyl ghrelin on gastric emptying and intestinal transit, suggesting that the prokinetic effects of acyl ghrelin are exerted via the cholinergic pathway (Sallam et al., 2007). Therefore, acyl ghrelin may have a therapeutic potential for clinical burn patients with delayed upper gastrointestinal transit.

Postoperative ileus develops as a consequence of abdominal surgery or other major surgical procedures and is a generalized event involving the entire gastrointestinal tract and is not restricted to the region directly subjected to manipulation. Proposed mechanisms of postoperative ileus include the stimulation of neuronal responses, such as excitation of afferent neurons and activation of noradrenergic and noncholinergic neuronal pathways, and the induction of an intestinal inflammatory response (Greenwood-Van Meerveld, 2007). However, the treatment of postoperative ileus is very limited. To date, GHS-R1a agonists (i.e., acyl ghrelin, acyl ghrelin analog, and acyl ghrelin mimetic) are the only effective drugs for treating postoperative ileus. Intravenous acyl ghrelin significantly reversed postoperative gastric and small intestinal ileus but not colonic ileus in rats (Trudel et al., 2002), whereas high doses of motilin or erythromycin were ineffective, and postoperative gastric ileus was only partially improved by the calcitonin gene-related peptide receptor antagonist CGRP<sub>8–37</sub>. Subsequent experiments showed that CGRP<sub>8–37</sub> and acyl ghrelin were potent prokinetics, improving postoperative gastric ileus in dogs (Trudel et al., 2003). Intravenous administration of acyl ghrelin analog RC-1139 reversed not only postoperative gastric ileus but also morphine-induced gastric ileus in rats (Poitras et al., 2005). Single or triple intravenous boluses of TZP-101, a small-molecule GHS-R1a agonist with bioavailability superior to that of acyl ghrelin, were equally effective to abolish abdominal surgery-induced ileus, morphine-induced gastric ileus, small intestinal ileus (Venkova et al., 2007), and colonic ileus (Fraser et al., 2009) in rats. The prokinetic action of TZP-101 was more profound in the stomach than in the small intestine and colon. TZP-101 administration shortened the time to the first bowel movement in rats with postoperative ileus, and restored postsurgery morphine-induced decrease of cumulative fecal pellet output, as measured by the number of fecal pellets and the stool weight, but had no effect on postoperative morphine-induced anorexia and reduced body weight (Fraser et al., 2009). Therefore, TZP-101 may represent a new therapeutic approach for the treatment
of gastric, small intestinal, and colonic dysmotility in patients with postoperative ileus. Repetitive intravenous administration of ipamorelin, a novel synthetic GHS-R1a agonist, significantly increased laparotomy and intestinal manipulation-induced reduction of cumulative fecal pellet output, food intake and body weight in rats (Venkova et al., 2009), implying that postsurgical multiple intravenous bolus infusion of ipamorelin might ameliorate the symptoms in patients with postoperative ileus.

Meal gastric emptying was delayed in patients with functional dyspepsia (Takamori et al., 2007; Lee et al., 2009). However, plasma ghrelin levels showed no significant correlation with delayed gastric emptying (Takamori et al., 2007; Lee et al., 2009) or psychological disorders in these patients. Investigation with more subjects is necessary to determine the true roles of acyl and des-acyl ghrelin in functional dyspepsia.

Meal gastric emptying was delayed in patients with functional dyspepsia (Takamori et al., 2007; Lee et al., 2009). However, plasma ghrelin levels showed no significant correlation with delayed gastric emptying (Takamori et al., 2007; Lee et al., 2009) or psychological disorders in these patients. Investigation with more subjects is necessary to determine the true roles of acyl and des-acyl ghrelin in functional dyspepsia.

**IX. Access of Ghrelin Gene Products to the Central Nervous System: Direct and Indirect Neuroendocrine Pathways**

Blood-born acyl ghrelin, secreted by gastric X/A cells, was originally thought to stimulate food intake by acting in the hypothalamic arcuate nucleus, which is devoid of blood-brain barrier, based on the presence of GHS-R1a there and the fact that acyl ghrelin, injected directly into the arcuate nucleus, induced eating (Wren et al., 2001b; Bagnasco et al., 2003; Currie et al., 2005). Rats with lesions in the area postrema, a caudal brain stem center devoid of blood-brain barrier, did not respond to peripheral acyl ghrelin-induced stimulation of food intake (Gilg and Lutz, 2006). A recent patch-clamp electrophysiologic study showed that acyl ghrelin exerted a direct effect on electrical activity of neurons in the area postrema, another brain region lacking the blood-brain barrier, supporting the notion that acyl ghrelin could act via the area postrema to regulate feeding and energy homeostasis (Fry and Ferguson, 2009). In addition, electrophysiological recordings found that acyl ghrelin stimulated the activity of arcuate NPY neurons and mimicked the effect of NPY in the paraventricular nucleus of the hypothalamus, revealing that release of acyl ghrelin at the arcuate nucleus and hypothalamic paraventricular nucleus might stimulate the release of orexigenic peptides and neurotransmitters, thus representing a regulatory circuit controlling energy homeostasis (Cowley et al., 2003). Administration of acyl ghrelin into the three other brain sites, including the hypothalamic paraventricular nucleus (Wren et al., 2001b; Olszewski et al., 2003a; Currie et al., 2005), the ventral tegmental area (Naleid et al., 2005; Abizaid et al., 2006; Jerlhag et al., 2007), and the dorsal vagal complex (Faulconbridge et al., 2003), also enhanced feeding. Furthermore, GHS-R1a mRNA is present in numerous other brain regions in which the effects of acyl ghrelin have not been explored (Zigman et al., 2006). Central acyl ghrelin injection, including ventricular, lateral hypothalamus, and paraventricular nucleus, recruiting oxytocin and orexin neurons (Olszewski et al., 2003b, 2007), induced feeding driven by energy needs not reward, as evidences by increased intake of chow but not sucrose in rats treated with central acyl ghrelin (Bomberg et al., 2007). Pharmacokinetic studies also identified the saturable systems transported human acyl ghrelin from brain to blood and from blood to brain, whereas mouse acyl ghrelin was a substrate for the brain-to-blood transporter but not for the blood-to-brain transporter (Banks et al., 2002) (also see Fig. 3).

Several studies suggested that peripheral acyl ghrelin stimulates feeding via a vagally mediated abdominal action. First, electrophysiologic evidence demonstrated that acyl ghrelin directly suppressed firing of gastric vagal nerves (Asakawa et al., 2001b; Date et al., 2002) and inhibited visceral afferent activation of cholecystokinin-sensitive catecholamine neurons in the solitary tract nucleus (Cui and Appleyard, 2009). Second, either total subdiaphragmatic vagotomy, selective gastric vagotomy, or perivagal capsaicin application blocked the feeding-stimulatory effect of intravenous or intraperitoneal injection of acyl ghrelin in rats (Date et al., 2002; Chen et al., 2005b) and mice (Asakawa et al., 2001b). Third, intravenous administration of acyl ghrelin stimulated GH secretion, but failed to enhance energy intake in patients who had undergone vagotomy as a result of lower esophageal or gastric surgery (le Roux et al., 2005a). Finally, peripheral acyl ghrelin elicited c-fos immunoreactivity in the arcuate nucleus (Date et al., 2002, 2005; Chen et al., 2005b; Kobelt et al., 2005; Inhoff et al., 2008), paraventricular nucleus (Chen et al., 2005b), and solitary tract nucleus (Date et al., 2005), whereas capsaicin treatment or coadministration of cholecystokinin abolished acyl ghrelin-induced neuronal activity in either the arcuate nucleus (Date et al., 2002; Kobelt et al., 2005) or solitary tract nucleus (Date et al., 2005). Collectively, these results support the important roles of peripheral acyl ghrelin in the activation of vagal afferent-solitary tract nucleus–arcuate nucleus/paraventricular nucleus pathways in stimulating food intake. However, another two studies showed that vagal afferents were not necessary for eating-stimulatory effect of intraperitoneal injected acyl ghrelin (Arnold et al., 2006), and hindbrain catecholamine neurons only contributed to the GH but not the feeding response to peripheral acyl ghrelin (Emanuel et al., 2009) in rats. Hence, more evidence is required to validate the role of vagal afferent nerves in mediating GH-releasing and appetite-stimulating effects.

Hypophysectomy prevented acyl ghrelin-induced adiposity and increased gastric ghrelin secretion in rats, suggesting a negative gastro-hypophysal regulatory feedback loop involving the stomach and the pituitary to regulate gastric ghrelin secretion (Tschöp et al., 2002).
Arcuate nucleus neurons, with projections to the median eminence, are well known to be responsive to a wide array of hormones and nutrients, including leptin, insulin, gonadal steroids, and glucose and to act as conduits or conditional pacemakers for diverse signals relevant to feeding and energy homeostasis (Cone et al., 2001; van den Top et al., 2004). Hence, reciprocal afferent humoral signals, composed of anorexigenic leptin from white adipose tissue and orexigenic acyl ghrelin from stomach, to the arcuate nucleus integrate the moment-to-moment regulation of energy homeostasis (Kalra and Kalra, 2004). Whole-cell patch-clamp recordings from rat arcuate nucleus neurons in hypothalamic slice preparations revealed widespread expression of functional ATP-sensitive potassium channels within the nucleus (van den Top et al., 2007). ATP-sensitive potassium channels were expressed in orexigenic NPY/AgRP and ghrelin-sensitive neurons and in anorexigenic CART neurons, indicating a crucial role for these ion channels in central sensing of metabolic and energy status (van den Top et al., 2007). Several in vivo lines of evidence, using either chemical ablation (Tamura et al., 2002) or vector-mediated ablation (Bewick et al., 2005) of NPY/AgRP neurons, or \( \text{NPY}(-/-)/\text{AgRP}(-/-) \) double knockout techniques (Chen et al., 2004), suggest that the orexigenic action of acyl ghrelin is mediated through NPY/AgRP neurons in the arcuate nucleus, because these NPY/AgRP neuron-manipulated animals, which were often lean and of a hypophagic phenotype, failed to respond to the feeding-stimulating effects of peripheral acyl ghrelin and of a hypophagic phenotype, failed to respond to AgRP neuron-manipulated animals, which were often lean and of a hypophagic phenotype, failed to respond to acyl ghrelin, elucidating that GABA release from AgRP neurons is important in regulating acyl ghrelin-mediated food intake and energy balance (Tong et al., 2008). Acyl ghrelin is known to activate hypothalamic AMPK, a crucial metabolic sensor controlling energy balance. A recent study showed that CaMKK2 mediated this effect by forming a unique complex of AMPK\(\alpha/\beta \) with acetyl-CoA carboxylase in a pathway distinct from the more established AMP/LKB1 pathway (Anderson et al., 2008). Short-term pharmacologic inhibition of CaMKK2 in wild-type mice, but not \( \text{CaMKK2}-\text{null} \) mice, inhibited appetite and promoted weight loss consistent with decreased NPY and AgRP mRNAs (Anderson et al., 2008). In mice, acyl ghrelin was found to initiate robust changes in hypothalamic mitochondrial respiration that were dependent on UCP2, whereas activation of this mitochondrial mechanism was critical for acyl ghrelin-induced mitochondrial proliferation and electric activation of NPY/AgRP neurons, for acyl ghrelin-triggered synaptic plasticity of POMC-expressing neurons, and for acyl ghrelin-induced food intake (Andrews et al., 2008). The UCP2-dependent action of acyl ghrelin on NPY/AgRP neurons was driven by a hypothalamic fatty acid oxidation pathway involving AMPK, carnitine palmitoyltransferase 1, and free radicals that were scavenged by UCP2, revealing a signaling modality connecting mitochondria-mediated effects of GPR on neuronal function and associated ingestive behavior (Andrews et al., 2008). Taken together, these results extend our understanding of the molecular basis and intracellular mechanisms, certainly including the imperative roles of NPY/AgRP neurons in the arcuate nucleus and hypothalamic AMPK/UCP2 system involved in the effect of acyl ghrelin on food intake and GH secretion.

Des-acyl ghrelin does not bind to GHS-R1a, but it crosses the blood-brain barrier to the brain by a non saturable transmembrane diffusion manner (Banks et al., 2002). Several results support the idea that peripheral des-acyl ghrelin, also secreted by gastric X/A cells, acts directly in the brain to inhibit feeding. First, intraperitoneal administration of des-acyl ghrelin suppressed food intake in lean mice and rats (Asakawa et al., 2005; Chen et al., 2005b), and food intake and body weight gain in obese Zucker rats (Stengel et al., 2008). Second, perivagal capsaicin application did not abolish the food-inhibitory effect of intraperitoneal administration of des-acyl ghrelin in rats (Chen et al., 2005b). Third, intraperitoneal injection of des-acyl ghrelin induced mRNA expression of CART and urocortin 1 in mice (Asakawa et al., 2005), which are both anorectic neu-
ropptides. Fourth, peripheral des-acyl ghrelin elicited c-fos immunoreactivity in the arcuate nucleus (Asakawa et al., 2005; Chen et al., 2005b; Stengel et al., 2008) and paraventricular nucleus (Asakawa et al., 2005; Chen et al., 2005b; Stengel et al., 2008) without change in the solitary tract nucleus (Chen et al., 2005b), indicating that the activation of des-acyl ghrelin on brain neurons was devoid of a vagal afferent nerve-solitary tract nucleus pathway. Fifth, intraperitoneal des-acyl ghrelin attenuated acyl ghrelin-induced c-fos immunoreactivity in the arcuate nucleus in lean rats (Inhoff et al., 2008). Sixth, pharmacological blockage revealed CRF$_2$-R to be responsible for the activation of des-acyl ghrelin actions on the brain. Seventh, immunofluorescence double staining confirmed colocalization of c-fos and CRF in the paraventricular nucleus in the hypothalamus by intraperitoneal injection of des-acyl ghrelin in rats (Chen et al., 2005b). Finally, pharmacokinetic experiments detected that des-acyl ghrelin entered the brain by nonsaturable transmembrane diffusion and was sequestered once within the central nervous system to mediate its actions there (Banks et al., 2002).

The biological actions and signaling pathway of obestatin are still debatable. Intravenous obestatin elicited c-fos immunoreactivity in the arcuate nucleus, paraventricular nucleus, and solitary tract nucleus (Ataka et al., 2008), implying that the vagal afferent pathway was involved, at least partially, in actions of peripheral obestatin activating the brain neurons. Pharmacological blockage revealed both CRF$_1$-R and CRF$_2$-R responsible for the activation of obestatin actions on the brain. Immunohistochemical analysis demonstrated that CRF- and urocortin-2-containing neurons in the paraventricular nucleus in the hypothalamus were activated by intravenous injection of obestatin in rats (Ataka et al., 2008; Fujimiya et al., 2008). However, another study claimed that intraperitoneal administration of obestatin did not elicit c-fos immunoreactivity in ingestive behavior-relevant brain nuclei in rodents (Kobelt et al., 2008). The rapid intracellular degradation and major instability of obestatin in the plasma should be taken into account during data interpretation (Pan et al., 2006; Vergote et al., 2008).

**X. Direct Effects of Ghrelin Gene Products on Other Tissues**

**A. Glucose Metabolism**

A previous study indicated that acyl ghrelin possessed insulin-like action stimulating the receptor substrate 1–growth factor receptor-bound protein 2–mitogen-activated protein kinase pathway and anti-insulin action suppressing Akt activity and up-regulation of gluconeogenesis in hepatoma cell lines (Murata et al., 2002). This raises the possibility of acyl ghrelin’s involvement in the regulation of glucose homeostasis and insulin secretion. Aeryl ghrelin induced several genes, including IA-2$\beta$, a pancreas $\beta$-cell autoantigen for type 1 diabetes (Doi et al., 2006). Administration of acyl ghrelin or overexpression of IA-2$\beta$ inhibited glucose-stimulated insulin secretion in MIN6 insulinoma cells. Furthermore, inhibition of IA-2$\beta$ expression by the RNA interference technique ameliorated acyl ghrelin-related inhibitory effects on glucose-stimulated insulin secretion (Doi et al., 2006), implying the link among acyl ghrelin, IA-2$\beta$, and glucose-stimulated insulin secretion. In vitro, acyl ghrelin elicited glucose output whereas des-acyl ghrelin suppressed glucose release by primary hepatocytes (Gauna et al., 2005). In addition, des-acyl ghrelin was able to antagonize acyl ghrelin-induced glucose output through a GHS-R1a independent pathway (Gauna et al., 2005), suggesting that acyl and des-acyl ghrelin could be separate hormones able to modulate hepatic glucose metabolism by acting directly on the liver.

Exogenous injection of acyl ghrelin at specific doses inhibited intravenous glucose-stimulated insulin secretion in mice by a direct action on the islets, most likely by a distal action on the $\beta$-cell signaling machinery (Reimer et al., 2003). GHS-R1a antagonist, [D-Lys$^3$]GHRP-6, and immunoneutralization of endogenous acyl ghrelin enhanced glucose-induced insulin release from perfused pancreas, whereas exogenous acyl ghrelin suppressed it ex vivo (Dezaki et al., 2006). In addition, acyl ghrelin inhibited insulin release from islets isolated from mice and rat pancreas, whereas des-acyl ghrelin blunted acyl ghrelin’s effect at a 10-fold higher concentration ex vivo (Qader et al., 2008). Aetyl ghrelin has been reported to activate GHS-R1a of pancreatic $\beta$-cells, which is coupled with pertussis toxin-sensitive heterotrimeric G-protein $\Gamma_{1_{12}}$, which in turn attenuates membrane excitability via activation of voltage-dependent K$^+$ channels (Kv2.1) and eventually suppresses Ca$^{2+}$ influx and insulin secretion ex vivo (Dezaki et al., 2004, 2007) (Fig. 5).

Exogenous acyl ghrelin administration produced higher blood glucose and marked lower insulin levels after intraperitoneal glucose injection in mice, implying that short-term administration of acyl ghrelin might suppress insulin release in vivo (Sun et al., 2006). Aetyl ghrelin infused into the portal vein inhibited glucose-stimulated insulin secretion in anesthetized rats, whereas the effect was attenuated by either hepatic vagotomy or coinfusion with atropine methyl bromide, supporting the inhibitory effect of exogenous acyl ghrelin on glucose-induced insulin release via the vagus nerve (Cui et al., 2008). The decrease in acyl ghrelin level after a meal might be important for the occurrence of the incretin effect in rats (Cui et al., 2008). Subsequent human studies demonstrated that exogenous acyl ghrelin exerted effects at a similar level to decrease plasma insulin and increase plasma glucose levels in young and elderly normal volunteers (Broglio et al., 2001, 2003a); administration of acyl ghrelin was followed by transient insulin release during oral free fatty acid loading, whereas acyl ghrelin blunted the insulin
response to arginine and enhanced arginine-induced increase in glucose level in healthy humans (Broglio et al., 2003b). Intravenous infusion of acyl ghrelin suppressed plasma insulin concentration with hyperglycemia in normal weight healthy volunteers (Arosio et al., 2003). Supraphysiological acyl ghrelin levels impaired human insulin sensitivity (Vestergaard et al., 2007b). The above four human studies support the existence of a functional link between acyl ghrelin and the endocrine pancreas.

By contrast, des-acyl ghrelin administration potently and dose-dependently increased insulin concentration induced by intravenous glucose tolerance test in the portal, and, to a lesser extent, the systemic circulation in anesthetized fasted rats (Gauna et al., 2007a). The des-acyl ghrelin-induced stimulation of insulin secretion was completely blocked by coadministration of exogenous acyl ghrelin at equimolar concentrations. Likewise, [d-Lys3]GHRP-6, alone or in combination with acyl ghrelin and des-acyl ghrelin, enhanced the portal insulin response to intravenous glucose tolerance test, whereas exogenous acyl ghrelin alone exert no further effect in vivo (Gauna et al., 2007a). In patients with GH deficiency, intravenous administration of acyl ghrelin reduced insulin sensitivity, whereas combination of acyl plus des-acyl ghrelin strongly improved insulin sensitivity (Gauna et al., 2004). Furthermore, intravenous acyl ghrelin increased plasma glucose and decrease plasma insulin levels, whereas des-acyl ghrelin coadministered with acyl ghrelin abolished these effects in healthy volunteers (Broglio et al., 2004b), suggesting that des-acyl ghrelin counteracts the metabolic response to acyl ghrelin in humans. Most recently, continuous exposure to acyl ghrelin in humans enhanced somatotroph secretion but also worsened glucose metabolism, although it inhibited lipolysis (Broglio et al., 2008). Coadministration of acyl ghrelin and des-acyl ghrelin as a single intravenous bolus injection caused a significant decrease in insulin concentration in nondiabetic subjects suffering from morbid obesity, a condition characterized by insulin resistance and low GH levels, whereas glucose concentration did not change in the first hour after combination administration of acyl ghrelin and des-acyl ghrelin (Kiewiet et al., 2009), suggesting a strong improvement in insulin sensitivity. Further human studies in which des-acyl ghrelin with or without acyl ghrelin administered for a longer time are warranted. Hence, des-acyl ghrelin, or more likely the acyl versus des-acyl ghrelin ratio, may be implicated in the regulation of insulin release. Des-acyl ghrelin may act as a secretagogue of insulin by removing the suppressive tone of acyl ghrelin on pancreatic β-cells and subsequently stimulate insulin secretion from pancreatic islets. The other speculation is that the relative increase of des-acyl ghrelin fraction in the peripheral circulation reflects the buffering of acyl ghrelin metabolic actions, thus improving peripheral insulin sensitivity (Gauna et al., 2007b). Therefore, des-acyl ghrelin might be of therapeutic value to treat insulin resistance and impaired insulin release in patients with type 2 diabetes.
On the other hand, short-term nutritional changes, such as short-term enteral or parenteral administration, may differentially regulate acyl and des-acyl ghrelin concentrations. For example, a short-term intravenous glucose load in anesthetized fasted rats inhibited des-acyl ghrelin in portal and systemic circulation, whereas it blunted acyl ghrelin concentration in only prehepatic but not systemic circulation (Gauna et al., 2007b). Secretion of total ghrelin was inhibited by glucose load, via either oral (Nakagawa et al., 2002; Broglio et al., 2004b) or intravenous (Nakagawa et al., 2002) route, but was unaffected by intravenous glucagons and arginine in humans.

The data concerning the influence of obestatin on glucose metabolism are controversial. Exogenous obestatin acted as a potent inhibitor of insulin secretion (similar to acyl ghrelin) under glucose-stimulated conditions in anesthetized fasted rats in vivo and in cultured islets in vitro (Ren et al., 2008). Exogenous obestatin was shown to inhibit insulin release from mouse and rat pancreas isolated islets ex vivo (Qader et al., 2008). Intraportal administration of obestatin inhibited feeding-induced elevation of plasma glucose and insulin levels in mice but exhibited no direct actions on glucose homeostasis or insulin secretion (Green et al., 2007). However, another study indicated that intravenous obestatin affected neither basal nor intravenous glucose-stimulated insulin secretion and glucose metabolism in the systemic and portal circulation of fasted rats (Kiewiet et al., 2008). Furthermore, incubation with obestatin did not alter insulin release from pancreatic islets and modify blood glucose (Unniappan et al., 2008), which did not support the notion that obestatin was a hormone with metabolic actions. On the contrary, obestatin increased insulin secretion in both absence and presence of glucose, stimulated the expression of main regulatory β-cell genes, and promoted β-cell and human islet cell survival in vitro (Granata et al., 2008). A recent study demonstrated that obestatin exerted a dual effect on glucose-induced insulin secretion in a perfused rat pancreas model: obestatin potentiated the insulin response to glucose at a low concentration, whereas it inhibited the insulin release evoked by glucose stimulus (Egido et al., 2009). The discrepancy regarding obestatin modulating glucose metabolism and insulin action needs further investigation.

Genetic studies also support the involvement of acyl ghrelin, des-acyl ghrelin, and GHS-R, in the regulation of glucose metabolism. First, acyl ghrelin-knockout mice displayed enhanced glucose-induced insulin release from isolated pancreatic islets ex vivo, whereas islet density, size, insulin content, and insulin mRNA levels were unaltered (Dezaki et al., 2006). Second, acyl ghrelin knockout mice had higher plasma insulin and lower blood glucose levels after intraperitoneal glucose injection and possessed a higher glucose disposal rate in hyperinsulinemic-euglycemic clamp studies compared with wild-type mice (Sun et al., 2006). Third, insulin-induced blood-glucose-lowering effect was greatly enhanced in mice lacking acyl ghrelin compared with wild-type control mice (Sun et al., 2006). Fourth, deletion of acyl ghrelin exhibited lower fasting blood glucose, higher fasting plasma C-peptide, and higher postprandial plasma insulin level in ob/ob mice (Sun et al., 2006). Fifth, double knockout of acyl ghrelin and leptin manifested higher plasma insulin secretion and prevented hyperglycemia induced by intraperitoneal glucose injection, compared with ob/ob mice (Sun et al., 2006). The authors suggested that ablation of acyl ghrelin rescued diabetic phenotype of ob/ob mice through augmenting glucose-dependent insulin secretion from the pancreas β-cells by reducing pancreatic Ucp2 expression and improving peripheral insulin sensitivity (Sun et al., 2006). In another two studies, absence of acyl ghrelin protected against hyperinsulinemia and hyperglycemia induced by a high-fat diet (Wortley et al., 2005; Dezaki et al., 2006). In addition, mice lacking GHS-R demonstrated lower blood glucose and serum insulin compared with wild-type control mice (Zigman et al., 2005; Longo et al., 2008; Sun et al., 2008) and greater "metabolic flexibility" under diet-induced metabolic stress in terms of utilization of energy (Longo et al., 2008). Furthermore, blood glucose levels fell in wild-type mice and in both acyl ghrelin-null and GHS-R-null genotypes, but the drop in blood glucose was significantly greater in acyl ghrelin knockout and GHS-R knockout mice than in their wild-type littermates during negative energy balance by 50% caloric restriction (Sun et al., 2008). On the other hand, age-related glucose intolerance was observed in a gain-of-function genetic model of increased circulating acyl ghrelin in transgenic mice (Reed et al., 2008). More recently, another study using transgenic mice indicated that overexpression of plasma acyl ghrelin was associated with hyperphagia, increased energy expenditure, glucose intolerance, decreased glucose-stimulated insulin secretion, and reduced leptin sensitivity (Bewick et al., 2009). Collectively, acyl ghrelin does play a fundamental role in regulating pancreatic β-cell function by inhibiting glucose-stimulated insulin release. The results imply that strategies designed to antagonize acyl ghrelin action may reduce appetite and improve glucose homeostasis (Bewick et al., 2009). By contrast, transgenic mice overexpressing des-acyl ghrelin exhibited lower blood glucose (Zhang et al., 2008b) and lower plasma insulin (Iwakura et al., 2005) levels after intraperitoneal glucose injection and had a greater hypoglycemic response to insulin administration (Zhang et al., 2008b) than control animals. However, other studies indicated that transgenic mice overexpressing des-acyl ghrelin showed small phenotype (Ariyasu et al., 2005; Asakawa et al., 2005), and tendencies with lower blood glucose and plasma insulin levels. It is conceivable that these genetic data imply the differential roles of acyl versus des-acyl ghrelin: acyl ghrelin may inhibit insulin...
release, decrease insulin sensitivity, and predispose to hyperglycemia, whereas des-acyl ghrelin may enhance insulin sensitivity and maintain a euglycemic condition.

In humans, acyl ghrelin peaks anticipated food episodes and were coupled with the lowest insulin levels, whereas food intake was followed by a prompt decrease in ghrelin coupled with an increase in insulin levels (Cummings et al., 2001), supporting a negative functional relationship between insulin and ghrelin secretion under normal physiologic conditions (Purnell et al., 2003; Cummings et al., 2004). An ex vivo study from a novel organ-culture model of gastric tissue explants from rat donors also confirmed this negative association: fasting induced elevation of plasma ghrelin level and suppression of plasma insulin concentration, whereas refeeding or “tease feeding” reversed them (Seoane et al., 2007b). A human study revealed that acyl ghrelin was negatively correlated with circulating insulin levels across all meals, and they suggested that insulin was a key determinant of meal-induced acyl ghrelin suppression (Tannous et al., 2008). However, plasma acyl and total ghrelin levels were enhanced in rats with streptozotocin-induced diabetes, suggesting adaptation to the negative energy balance condition (Masaoka et al., 2003). Likewise, plasma fasting acyl ghrelin level was increased, whereas des-acyl ghrelin level was decreased in patients with obesity-related type 2 diabetes compared with lean subjects (Rodriguez et al., 2009). Moreover, plasma total ghrelin level negatively correlated with hemoglobin A1c in patients with diabetes, suggesting that long-term poor glycemic control might impair ghrelin secretion (Ueno et al., 2007). A recent study indicated that metformin therapy prolonged the postprandial fall of plasma total ghrelin concentration and thus had concomitant effects on appetite in type 2 diabetes, contributing to its actions in promoting weight loss and attenuating weight gain in these patients (English et al., 2007).

Overall, the ghrelin system plays a pivotal role in the enteroinsular axis. Acyl ghrelin influences glucose metabolism not only from its endocrine effect, but also from its direct effects on hepatocytes by stimulating hepatic glucose production (Murata et al., 2002; Gauna et al., 2005). In addition, acyl ghrelin inhibited secretion of the insulin-sensitizing protein adiponectin from adipocytes (Ott et al., 2002) and stimulated release of the counter-regulatory hormones, including GH (Broglio et al., 2001, 2003a, 2004c), cortisol, epinephrine (Broglio et al., 2003a, 2004c), and possibly glucagon, pancreatic polypeptide, and somatostatin (Qader et al., 2008) (Fig. 5). The effects of acyl ghrelin on glucose metabolism and insulin secretion should be mediated by GHS-R1a, whereas those of des-acyl ghrelin might be mediated through a receptor other than GHS-R1a (Soares and Leite-Moreira, 2008). In clinical practice, bariatric surgery is a promising mode to resolve human type 2 diabetes mellitus (Vetter et al., 2009). Diabetes resolves 84 to 98% after bypass procedure and 48 to 68% for restrictive procedure. Bariatric surgery alters secretion of gut hormones, resulting in enhanced insulin secretion and improved glycemic control in humans (Vetter et al., 2009). However, effects of gastric bypass on ghrelin levels are inconsistent (Vetter et al., 2009). Two recent studies pointed out that measurement of total ghrelin did not adequately reflect acyl ghrelin and des-acyl ghrelin concentrations, which highlights the importance of evaluation of acyl ghrelin and des-acyl ghrelin using specific two-site assays (Mackelvie et al., 2007; Liu et al., 2008). Hence, further studies, particularly using state-of-art technique to separately measure acyl ghrelin, des-acyl ghrelin, and obestatin, are necessary to clarify this controversial issue, and facilitate refinement of surgical procedures and development of drugs with the same effects but without using a “knife.”

B. Lipid Metabolism

Des-acyl ghrelin, acyl ghrelin, short acyl ghrelin fragments, and synthetic GHS were shown to act directly as antilipolytic factors on the adipose tissue in vitro through binding to a specific receptor that is distinct from GHS-R1a (Muccioli et al., 2004). Acyl and des-acyl ghrelin were expressed in human abdominal-subcutaneous adipose tissue (Kos et al., 2009). Both acyl and des-acyl ghrelin mediated fat deposition in part via Y1 receptor, whereas des-acyl ghrelin affected lipolysis, lipogenesis, and leptin secretion (Kos et al., 2009). The results suggest the potential importance of the gut-fatbrain axis in determining ghrelin’s effects on lipid metabolism. In differentiating omental adipocytes, incubation with both acyl and des-acyl ghrelin significantly increased peroxisome proliferator-activated receptor γ and sterol-regulatory element binding protein-1 mRNA levels, as well as fat storage-related proteins, including acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase, and perilipin (Rodriguez et al., 2009). Consequently, both acyl and des-acyl ghrelin stimulated intracytoplasmic lipid accumulation (Rodriguez et al., 2009). A study indicated that both cannabinoids and acyl ghrelin stimulated AMPK activity in the hypothalamus and the heart but inhibited AMPK in liver and adipose tissue (Kola et al., 2005). The activation of AMPK through phosphorylation resulted in decreased hypothalamic levels of malonyl-CoA and increased carnitine palmitoyltransferase 1 (López et al., 2008). These novel effects of cannabinoids and acyl ghrelin on AMPK provide a mechanism for an increase in adipose tissue, in addition to the well known stimulation of appetite. The effects of ghrelin on lipogenesis (lipogenic) and carbohydrate metabolism (diabetogenic) can also be explained by its ability to activate AMPK.

Subcutaneous injection of acyl ghrelin in rats induced tissue-specific changes in mitochondrial and lipid metabolism genes favoring triglyceride deposition in liver over skeletal muscle (Barazzoni et al., 2005). Long-term
intravenous infusion of acyl ghrelin, but not des-acyl ghrelin, induced a depot-specific increase in white adipose tissue in retroperitoneal and inguinal regions and promoted hepatic steatosis in rats by a GHS-R1a-dependent lipid retention mechanism (Davies et al., 2009). Direct injection of acyl and des-acyl ghrelin, but not GHS-R1a agonist (L-163,255), into the right tibial bone marrow cavity promoted bone marrow adipogenesis in rats (Thompson et al., 2004). The in vivo experiment demonstrated that the direct adipogenic effects of acyl and des-acyl ghrelin were mediated by a receptor other than GHS-R1a and were independent of GH secretion. Central acyl ghrelin is of physiological relevance in the control of cell metabolism in adipose tissue, because it induces adiposity (Tschoëp et al., 2000) and stimulates lipid storage (Theander-Carrillo et al., 2006) independently from acyl ghrelin-induced hyperphagia and seems to be mediated by the sympathetic nervous system (Theander-Carrillo et al., 2006). Most recently, central acyl ghrelin was demonstrated to regulate peripheral lipid metabolism in a GH-independent fashion (Sangiiao-Alvarellos et al., 2009). These results imply a new central nervous system-based neuroendocrine circuit regulating metabolic homeostasis of adipose tissue.

On the other way, free fatty acids in physiological range had an independent suppressive effect on plasma total ghrelin level in humans, serving as a negative feedback control, whereas this effect was evident with intra-arterial free fatty acid concentration between 0 and 1 nM (Gormsen et al., 2006). Moreover, neither GH nor GHS-R blockade (using pegvisomant) had any effect on circulating total ghrelin concentrations (Gormsen et al., 2007).

Regarding obestatin, the N-terminal (residues 1–13) reduced cholesterol and triglyceride levels and perirenal and epididymal fat, whereas the middle fragment (residues 6–18) reduced triglyceride levels and epididymal fat in mice (Nagaraj et al., 2008).

C. Cardiovascular System

Widespread expression of ghrelin and GHS-R1a was shown in the human cardiovascular system (Klein et al., 2006). Therefore, it is intriguing to speculate about the link among ghrelin, obesity, and major cardiovascular comorbidities, such as hypertension, atherosclerosis, and heart disease. Acyl ghrelin has been demonstrated to exhibit direct vasodilatory effects in humans. Short-term intra-arterial infusion of human acyl ghrelin increased forearm blood flow in healthy volunteers in a dose-dependent manner (Okumura et al., 2002). Short-term intravenous infusion of acyl ghrelin decreased mean arterial pressure, increased cardiac index and stroke volume index, and elicited GH, prolactin, adrenergic, corticotropin, cortisol, and epinephrine secretion, but with no alteration in heart rate in healthy subjects (Nagaya et al., 2001a). These direct vasodilatory effects were through endothelium-independent, antagonizing in vitro vasoencontric action of endothelin-1 (Wiley and Davenport, 2002) and in vivo GH/IGF-1/nitric oxide-independent (Okumura et al., 2002) mechanisms. Micro-injection of both acyl and des-acyl ghrelin in the nucleus tractus solitarii decreases blood pressure in rats (Lin et al., 2004; Tsubota et al., 2005). Subcutaneous injection of acyl ghrelin attenuated the progression of long-term hypoxia-induced pulmonary hypertension in rats involving down-regulation of endothelin-1 and prevention of impaired NO-mediated vasodilation and thickened wall-to-lumen ratio in peripheral pulmonary arteries (Schwenke et al., 2008b). These results indicate that acyl ghrelin may be an effective prophylactic therapy for attenuating the adverse responses to chronic hypoxia.

Two endogenous ligands of GHS-R, acyl ghrelin and des-Gln¹⁴-ghrelin, as well as des-acyl ghrelin, increase tension of guinea pig papillary muscle ex vivo (Bedendi et al., 2003). Ghrelin unexpectedly increased coronary perfusion pressure and constricted isolated coronary arterioles in rats (Pemberton et al., 2004), whereas intracoronary acyl ghrelin infusion unexpectedly decreased coronary blood flow in anesthetized pigs (Grossini et al., 2007). The mechanisms were shown to involve L-type Ca²⁺ channel and protein kinase C activation (Pemberton et al., 2004) and the inhibition of a tonic coronary β₂-adrenergic receptor-mediated vasodilatory effect related to the release of nitric oxide (Grossini et al., 2007). By contrast, subcutaneous injection of the GHS-R1a antagonist [D-Lys-3]GHRP-6 increased arterial pressure and heart rate dose-dependently via modulation of sympathetic activity in rats (Vlasova et al., 2009). Therefore, this finding raises the concern that the use of GHS-R1a antagonists as therapeutic targets for reduction in food intake might lead to serious side effects, such as elevated blood pressure in humans, most of whom already have elevated blood pressure as part of their metabolic syndrome (Vlasova et al., 2009). On the other hand, bolus intravenous injection of obestatin does not change blood pressure level of spontaneously hypertensive rat (Li et al., 2009).

Exogenous ghrelin inhibited vascular oxidative stress in spontaneously hypertensive rats as a result of inhibition of vascular NADPH oxidases (Kawczynska-Drozdz et al., 2006). The finding may indicate the potential and important antiatherosclerotic effect of ghrelin. Acyl ghrelin inhibited angiotensin II-induced proliferation and contraction in a dose-response manner via the cAMP/protein kinase A pathway (Rossi et al., 2009). Repeated administration of acyl ghrelin improved endothelial dysfunction and increased endothelial nitric-oxide synthase expression in GH-deficient rats, elucidating GH-independent mechanisms (Shimizu et al., 2003b). These data regarding the effects of acyl ghrelin on rodent and human aortic smooth muscle cell functions open the way to considering ghrelin as a potential therapeutic target in vascular damage and remodeling. The beneficial action of acyl ghrelin on human vascular endothelium has been
shown (Tesauro et al., 2005). However, total ghrelin concentrations and carotid artery atherosclerosis were found to be positively correlated in men after adjustment for the commonly recognized risk factors of atherosclerosis (Pöykkö et al., 2006). Therefore, experimental and prospective studies are warranted to clarify the roles of ghrelin in atherosclerosis. Novel vascular actions of acyl ghrelin were observed to directly stimulate production of NO from vascular endothelial cells using phosphoinositide-3-kinase-dependent signaling pathways that mimic those of insulin (Iantorno et al., 2007), implying that ghrelin could be beneficial for metabolic and cardiovascular diseases characterized by reciprocal relationships between insulin and endothelial dysfunction.

Exogenous administration of acyl ghrelin after rat myocardial infarction prevented an increase in cardiac sympathetic tone (Schwenke et al., 2008a; Soeki et al., 2008), attenuated early cardiac remodeling (Soeki et al., 2008), improved left ventricular function (Soeki et al., 2008), and reduced mortality (Schwenke et al., 2008a), implying that early acyl ghrelin treatment within the first several hours after myocardial infarction may improve early survival prognosis and provide clinicians with critical time for implementing supplementary therapeutic measures. In addition, ghrelin and GHS-R1a in the myocardium were up-regulated during isoproterenol-induced myocardial injury (Li et al., 2006). The protective effect of acyl ghrelin against isoproterenol-induced myocardial injury and fibrosis was more potent than that of des-acyl ghrelin, which suggests that acyl and des-acyl ghrelin could be an endogenous cardioprotective factor in ischemic heart disease (Chang et al., 2004; Li et al., 2006), and these effects were mediated via GHS-R1a-dependent and -independent pathways (Li et al., 2006). Subcutaneous or intravenous infusion of acyl ghrelin stimulated left ventricular function but not modified endothelium-dependent vasodilation, with (Enomoto et al., 2003) or without (Vestergaard et al., 2007a) altering ejection fraction in men. The beneficial effects of ghrelin on heart function, including reduction of myocyte apoptosis, can also be explained by its ability to activate AMPK (Kola et al., 2005).

D. Endocrine System

1. Hypothalamic-Pituitary-Adrenal Axis. Acyl ghrelin strongly stimulates GH secretion and facilitates secretion of GHRH. On the other hand, acyl ghrelin affects somatotropic and hypothalamic-pituitary-adrenal axis. In fact, acyl ghrelin induces secretion of adrenocorticotropic and cortisol/prolactin (or corticosterone) in humans (Takaya et al., 2000; Coiro et al., 2005) and rats (Asakawa et al., 2001a). Acyl ghrelin was shown to increase release of CRF in rats (Mozid et al., 2003) and arginine-vasopressin in humans (Coiro et al., 2005) and in rats (Ishizaki et al., 2002; Mozid et al., 2003). The mechanisms of GH and adrenocorticotropic regulation by acyl ghrelin may include hypothalamic release of GHRH, CRF, arginine vasopressin, and NPY (Wren et al., 2002).

Expression of prepro-ghrelin, GHS-R1a, and GOAT genes was notably higher in the cortex than in medulla, whereas high expression of GOAT gene was found in the zona glomerulosa. Direct stimulating effect of acyl ghrelin on corticosterone output by cultured rat adrenocortical cells was also demonstrated (Rucinski et al., 2009).

2. Hypothalamic-Pituitary-Thyroid Axis. Hypothyroidism resulted in an increase in gastric ghrelin mRNA and circulating plasma total ghrelin levels, both being decreased in hyperthyroid rats (Caminos et al., 2002). Reduced serum acyl ghrelin levels were observed in patients with hyperthyroidism (Riis et al., 2003; Röjdmark et al., 2005; Altinova et al., 2006a, 2006b; Braklik et al., 2008) but not in subclinical hyperthyroidism (Tanda et al., 2009). Ghrelin levels were decreased in hyperthyroidism and increased when euthyroidism was achieved after treatment with antithyroid drugs (Röjdmark et al., 2005; Tanda et al., 2009; Theodoropoulou et al., 2009). Body mass index and insulin were the main factors influencing ghrelin concentration in hyperthyroidism, whereas T3 and T4 levels had no effect on ghrelin levels (Theodoropoulou et al., 2009). GH release after acyl ghrelin, GHRP-6, and GHRH administration was decreased in thyrotoxicosis, whereas acyl ghrelin's ability to increase glucose levels was not altered in thyrotoxicosis (Nascif et al., 2007). Acyl ghrelin-mediated pathways of adrenocorticotropic hormone release might be activated by thyroid hormone excess, but adrenocortical reserve was maintained during thyrotoxicosis (Nascif et al., 2009). These observations suggest that thyroid hormone excess interferes with GH-releasing and affects adrenocorticotropic-releasing pathways activated by acyl ghrelin. Circulating total ghrelin in thyroid dysfunction was related to insulin resistance and not to hunger, food intake, or anthropometric changes (Giménez-Palop et al., 2005). Thyroid hormone stimulates food intake in humans and rodents. The hypothalamic neuropeptide YY/1 receptor pathway, activated by a reduction in circulating leptin but not by an increase in circulating ghrelin, contributed to hyperphagia associated with triiodothyronine-induced thyrotoxicosis (Ishii et al., 2003).

Hypothyroidism is not accompanied by significant changes in circulating ghrelin (Tanda et al., 2009). Serum ghrelin levels are increased in patients who are hypothyroid (Braklik et al., 2008; Gjedde et al., 2008) and become normalized by l-thyroxine treatment (Gjedde et al., 2008).

E. Cell Proliferation

Acyl and des-acyl ghrelin stimulated the proliferation of a somatotroph pituitary tumor cell line via the mitogen-activated protein kinase pathway (Nanzer et al., 2004). Because ghrelin has been shown to be expressed in both normal and adenomatous pituitary
tissue, locally produced acyl and des-acyl ghrelin may play a role in pituitary tumorigenesis via an autocrine/paracrine pathway. [³H]Thymidine incorporation with both hexarelin and acyl ghrelin was shown to be stimulated rat hippocampal progenitor cells (Johansson et al., 2008), suggesting a novel cell protective and proliferative role for GHS in the central nervous system. The third ghrelin gene, obestatin, was reported to mediate proliferation of human retinal pigment epithelium cells (Camina et al., 2007).

Natural (acyl ghrelin) and synthetic (hexarelin) GH secretagogues both were demonstrated to stimulate H9c2 cardiomyocyte cell proliferation, supporting the potential peripheral effects of GHS on the cardiovascular system independent of increased GH secretion (Pettersson et al., 2002). Both acyl ghrelin and des-acyl ghrelin have been reported to inhibit cell death in primary adult and H9c2 cardiomyocytes and endothelial cells through extracellular signal-regulated kinase 1/2 and phosphoinositide-3-kinase/AKT pathways (Baldanzi et al., 2002). Furthermore, acyl ghrelin and des-acyl ghrelin recognize common high-affinity binding sites on H9c2 cardiomyocytes, which do not express GHS-R (Baldanzi et al., 2002). The third ghrelin gene product, obestatin, was not a relevant metabolic or viability modifier on cardiomyocyte (Iglesias et al., 2007).

Both acyl ghrelin and des-acyl ghrelin were reported to stimulate proliferating C2C12 skeletal myoblasts, which did not express GHS-R1a, to differentiate and to fuse into multinucleated myotubes in vitro through activation of p38 (Filigheddu et al., 2007). The results provide the evidence that the described activities on C2C12 are probably mediated by this novel, as-yet unidentified receptor for both ghrelin forms.

Ghrelin and GHS-R production were demonstrated to be present in pancreatic β-cells and related endocrine tumors, indicating that autocrine/paracrine circuits of ghrelin/GHS-R may be active in neoplastic conditions (Volante et al., 2002). Des-acyl ghrelin and acyl ghrelin were also shown to prevent cell death and apoptosis of pancreatic β-cells, implying that an as-yet unknown receptor other than GHS-R1a was likely to be involved in these survival mechanisms (Granata et al., 2006). A subsequent study further identified that acyl ghrelin and des-acyl ghrelin promoted survival of both β-cells and human islets, whereas these effects were independent of GHS-R1a and were probably mediated by acyl ghrelin/des-acyl ghrelin binding sites and involved cAMP/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphoinositide-3-kinase/Akt signaling pathways (Granata et al., 2007). The third ghrelin gene product, obestatin, has been proven to promote β-cell and human islet cell survival and to stimulate the expression of main regulatory β-cell genes (Granata et al., 2008). Taken together, new roles for all three ghrelin gene products were identified within the endocrine pancreas.

Finally, the ghrelin system was shown to affect various cancer cell lines. For example, acyl ghrelin and des-acyl ghrelin induced in vitro a dose-dependent inhibition of cell proliferation and increased apoptosis of the H345 small cell carcinoma cell line, despite the absence of GHS-R1a (Cassoni et al., 2006), whereas acyl ghrelin and des-acyl ghrelin inhibited DU-145 cell proliferation, and displayed a biphasic effect in PC-3 cells in human prostate neoplasm-related cell lines via specific GHS binding sites other than GHS-R1a and -1b (Cassoni et al., 2004).

F. Immune Function

In fact, various studies reveal that acyl ghrelin regulates immune cell proliferation and activation and secretion of proinflammatory cytokines. Ghrelin stimulated phagocytosis through a GHS-R1a dependent pathway in fish, the most primitive vertebrate (Yada et al., 2006). Expressions of GHS-R1a and acyl ghrelin were detectable in all immune cells regardless of the maturity and cell types, including T cells, B cells, monocytes, and neutrophils (Hattori et al., 2001; Gnanapavan et al., 2002; Dixit et al., 2004), where acyl ghrelin acts via GHS-R1a to specifically inhibit the expression of proinflammatory anorectic cytokines such as interleukin-1β, interleukin-6, and TNF-α (Dixit et al., 2004). Acyl ghrelin was expressed in human T cells and preferentially segregated within the lipid raft domains upon T-cell antigen receptor ligation (Dixit et al., 2009). Genetic ablation of both acyl ghrelin and GHS-R1a led to loss of thymic epithelial cells and an increase in adipogenic fibroblasts in the thymus (Youm et al., 2009). Acyl ghrelin and GHS-R1a expression within the thymus diminished with progressive aging (Dixit et al., 2007), whereas infusion of acyl ghrelin into 14-month-old mice significantly improved the age-associated changes in thymic architecture and thymocyte numbers. In addition, acyl ghrelin expression also declined with increasing age in spleen and T cells, whereas exogenous acyl ghrelin administration in old mice reduced proinflammatory cytokines, showing that ghrelin functions in an autocrine and paracrine capacity to regulate proinflammatory cytokine expression in human and murine T cells and may contribute in regulating so called “inflamming” (Dixit et al., 2009). Acyl ghrelin-induced thymopoiesis during aging was associated with enhanced early thymocyte progenitors and bone marrow-derived Lin(−)Sca1(+)cKit(+) cells, whereas acyl ghrelin- and GHS-R-deficient mice displayed enhanced age-associated thymic involution (Dixit et al., 2007). Functional loss of acylghrelin/GHS-R1a interactions induced thymic adipogenesis with age, suggesting that acyl ghrelin may preserve the thymic stromal cell microenvironment by controlling age-related adipocyte development within the thymus (Youm et al., 2009). An age-related increase in thymic adiposity is associated with reduced thymopoiesis and compromised immune surveil-
lance in the elderly, which is a very clinically relevant issue.

In contrast, des-acyl ghrelin is not involved in immunomodulation (Li et al., 2004; Dixit et al., 2007). On the other hand, obestatin increases binding of oxidized low-density lipoprotein to thioglycollate-elicited mouse peritoneal macrophages, and when administered together with acyl ghrelin, decreased vascular cell adhesion molecule-1 expression on endothelial cells (Kellokoski et al., 2009).

G. Bone Metabolism

In healthy children, acyl ghrelin was a significant negative predictor of whole-body bone mineral density and bone mineral content, whereas in obese children, des-acyl ghrelin was found to be associated with whole-body bone mineral density, whole-body bone mineral content, and height (Pacifico et al., 2009). However, testosterone was reported to stimulate markers of bone formation (procollagen type N-terminal propeptide) and bone resorption (type I carboxyl-terminal telopeptide) in early puberty, whereas total ghrelin level had no direct influence on bone turnover markers in boys at different stages of puberty (Jüriämä et al., 2009b). In addition, ghrelin had no direct influence on bone mineral density in young male competitive swimmers (Jüriämä et al., 2009a). In elderly Italian men, serum ghrelin was significantly associated with femoral neck bone mineral density (Gonnelli et al., 2008). Exogenous infusion of acyl ghrelin had no immediate effects on bone resorption (as measured by type 1 collagen β C-telopeptide) and bone formation (as measured by procollagen type 1 amino-terminal propeptide) in healthy volunteers and subjects who had undergone gastrectomy (Huda et al., 2007). However, there was an inverse relationship between baseline total ghrelin and bone resorption (Huda et al., 2007). GOAT mRNA was expressed in murine cartilage explants and in the cultured murine chondrogenic ATDC-5 cell line. Likewise, GOAT was also expressed in human immortalized chondrocyte cell lines and in human cultured primary chondrocytes, demonstrating that chondrocytes were equipped with biochemical machinery for the synthesis of acylated ghrelin (Gómez et al., 2009). Moreover, ghrelin was synthesized and secreted by chondrocytes (Caminos et al., 2005). These data suggest a novel role of the ghrelin axis in prehypertrophic and hypertrophic chondrocyte differentiation during endochondral ossification.

Bone weight, bone mineral density and bone mineral content of the lumbar vertebrae and humerus were decreased in the fundectomized pigs compared with sham-operated pigs, in parallel with lower serum GH, ghrelin, and IGF-1 concentrations (Tatara et al., 2007). These findings established the role of the gastric-hypothalamic-pituitary axis in osteopenia. Subcutaneous injection of acyl ghrelin partially reversed total gastrectomy-induced reduction of body weight, lean body mass, and body fat but not bone mass in mice (Dornonville de la Cour et al., 2005). Ghrelin and GHS-R1a were identified in osteoblast-like cells (Fukushima et al., 2005). Acyl ghrelin stimulated proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway: acyl ghrelin bound to GHS-R1a on osteoblasts and induced NO production, and, in turn, NO stimulated cGMP production via activating guanylate cyclase (Wang et al., 2009a). Ghrelin increased osteoblast-like cell numbers and DNA synthesis, whereas the proliferative effects of ghrelin were abolished by the GHS-R1a antagonist d-Lys3GHRP-6 (Fukushima et al., 2005). In addition, ghrelin increased the expression of osteoblast differentiation markers and calcium accumulation in the matrix and bone mineral density in normal and GH-deficient rats (Fukushima et al., 2005). Furthermore, ghrelin stimulated intramembranous osteogenesis in rats (Deng et al., 2008). In addition to the GHS-R1a pathway, acyl and des-acyl ghrelin were demonstrated to stimulate human osteoblast growth via mitogen-activated protein kinase/phosphoinositide 3-kinase pathways in the absence of GHS-R1a in vitro (Delhanty et al., 2006). In addition to proliferative-stimulating effects, acyl ghrelin promoted differentiation (Kim et al., 2005b; Maccarinelli et al., 2005) and inhibited apoptosis (Kim et al., 2005b) in osteoblastic cells from cell culture experiments. Both immunocytochemistry and radioimmunoassay methods showed that ghrelin was detected mainly in the odontoblasts but also in the pulp of human canines and molars (Aydin et al., 2007b). Hence, ghrelin potentially plays interesting and important physiological roles in teeth. On the other hand, it probably plays a marginal role in the regulation of chondrocyte metabolism and only decreased the metabolic activity of chondrocytes (Lago et al., 2007).

H. Sleep

Intracerebroventricular acyl ghrelin induced increases in behavioral activity, including feeding, exploring, and grooming, and stimulated food and water intake in rats, supporting the roles of acyl ghrelin in the integration of feeding, metabolism, and sleep regulation (Szentirmai et al., 2006a). Acyl ghrelin depolarized laterodorsal tegmental nucleus neurons (Takano et al., 2009) and pedunculopontine tegmental nucleus (Kim et al., 2009) postsynaptically and dose dependently via GHS-R1a, and the ionic mechanisms underlying acyl ghrelin-induced depolarization included a decrease of K+ conductance. These findings provide electrophysiological bases to support the implication that laterodorsal tegmental nucleus neurons are involved in the cellular processes through which acyl ghrelin participates in the regulation of sleep-wakefulness. Different effects of exogenous acyl ghrelin and obestatin on sleep in rodents and humans are summarized in Table 4.

Reduced sleep duration and quality seem to be endemic in modern society. Subjects with short sleep had
reduced serum fasting leptin, elevated fasting total ghrelin, and increased body mass index (Taheri et al., 2004). Sleep was found to enhance nocturnal plasma total ghrelin surges in healthy subjects (Dzaja et al., 2004), whereas a blunting in the nocturnal rise in plasma total ghrelin concentration characterized obese subjects (Yildiz et al., 2004). The above evidence corroborates the assumption of a tight connection between sleep-wake modulation and metabolic parameters. A single night of sleep deprivation increased total ghrelin levels and feelings of hunger in normal-weight healthy men (Schmid et al., 2008), whereas another study revealed that a single sleep deprivation had relatively weak effect on plasma total ghrelin concentrations (Schüssler et al., 2006). Recurrent bedtime restriction can modify the amount, composition, and distribution of human food intake, and sleeping short hours in an obesity-promoting environment may facilitate the excessive consumption of energy from snacks but not meals (Nedeltcheva et al., 2009). These findings illustrate evidence of disturbing influence of sleep loss on endocrine regulation of energy homeostasis, which in the long run may result in altered ingestive behavior, weight gain, and obesity. Patients with chronic insomnia exhibited lower total ghrelin levels across the night (Motivala et al., 2009), indicating that besides short-term experimental sleep loss, long-term sleep difficulties are associated with altered ghrelin expression. The marked decrease in average sleep duration in the last 50 years, coinciding with the increased prevalence of obesity, together with the observed adverse effects of recurrent partial sleep deprivation on metabolism and hormonal processes, may have important implications for public health (Van Cauter et al., 2008).

### I. Memory

Ghrelin was found to be present in the majority of cultured newborn rat neurons (Stoyanova et al., 2009). Circulating acyl ghrelin was found to enter the hippocampus and to bind to neurons of the hippocampal formation, where it promoted dendritic spine synapse formation and generation of long-term potentiation (Diano et al., 2006). These ghrelin-induced synaptic changes were paralleled by enhanced spatial learning and memory. Targeted disruption of the gene encoding ghrelin resulted in decreased numbers of spine synapses in the CA1 region and impaired performance of mice in behavioral memory testing, both of which were rapidly reversed by acyl ghrelin administration (Diano et al., 2006). Effects of exogenous acyl ghrelin and obestatin on memory in rodents and chicks are summarized in Table 5. These observations reveal endogenous functions of

---

**TABLE 4**

Effects of acyl ghrelin and obestatin on sleep

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Animals Studied</th>
<th>Administration Routes with and without Acting Areas</th>
<th>Effects on Sleep</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyl ghrelin</td>
<td>Rats</td>
<td>Microinjection of into hypothalamic sites, such as the lateral hypothalamus, medial preoptic area, and paraventricular nucleus</td>
<td>↑ Wakefulness</td>
<td>Szentirmáni et al., 2007a</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Healthy males</td>
<td>i.v.</td>
<td>↑ Slow wave sleep</td>
<td>Weikel et al., 2003</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Young men</td>
<td>i.v.</td>
<td>↑ Non-REM sleep</td>
<td>Kluge et al., 2008</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Young women</td>
<td>i.v.</td>
<td>↓ Sleep pattern</td>
<td>Kluge et al., 2007</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Elderly men</td>
<td>i.v.</td>
<td>↑ Slow wave sleep and stage 2 sleep</td>
<td>Kluge et al., 2009</td>
</tr>
<tr>
<td>Obestatin</td>
<td>Elderly women</td>
<td>i.v.</td>
<td>↓ Stage 1 sleep and REM sleep</td>
<td>Kluge et al., 2009</td>
</tr>
<tr>
<td>N.A.</td>
<td>Preproghrelin gene KO mice</td>
<td>N.A.</td>
<td>— Sleep pattern</td>
<td>Szentirmáni and Krueger, 2006b</td>
</tr>
</tbody>
</table>

1. i.c.v., intracerebroventricular; i.v., intravenous; KO, knockout; REM, rapid eye movement; N.A., not applicable.

---

**TABLE 5**

Effects of acyl ghrelin and obestatin on memory

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Animals Studied</th>
<th>Administration Routes with and without Acting Areas</th>
<th>Effects on Memory Retention</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyl ghrelin</td>
<td>Rats</td>
<td>i.c.v. and microinjected into hippocampus, amygdala, and dorsal raphe nucleus</td>
<td>↑ Memory retention</td>
<td>Carlini et al., 2002, 2004</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Mice</td>
<td>i.c.v.</td>
<td>Reversing decreased memory for novel object recognition in long-term food restriction</td>
<td>Carlini et al., 2008</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Neonatal chicks</td>
<td>i.c.v.</td>
<td>↓ Memory retention</td>
<td>Carvajal et al., 2009</td>
</tr>
<tr>
<td>Obestatin</td>
<td>Rats</td>
<td>i.c.v.</td>
<td>↑ Memory retention</td>
<td>Carlini et al., 2007b</td>
</tr>
</tbody>
</table>

i.c.v., intracerebroventricular.
A. Obesity

The ghrelin-GHS-R system is imperative in modulating appetite, energy expenditure, and body weight regulation. Given the growing epidemic of obesity, it is important to understand the complex physiological processes that regulate body weight, including the precise role of ghrelin in the involvement of the pathogenesis of overweight and obesity. In addition to inducing hyperphagia, peripheral administration of acyl ghrelin increases fat mass by reducing fat utilization, which results in body weight gain in mice (Tscho¨p et al., 2000) and obesity in rats (Wren et al., 2001b). These findings underline the role of acyl ghrelin in modulating energy homeostasis balance in addition to its hyperphagic effect. Weight gain by forced over-feeding in rats (Williams et al., 2006) or short-term over-eating in humans (Robertson et al., 2004) results in the decrease of circulating ghrelin. Obese rodents, including ob/ob and db/db mice and Zucker fatty rats, exhibited lower fasting total and acyl ghrelin levels than control animals (Ariyasu et al., 2002). Plasma total ghrelin concentration was decreased, whereas insulin and leptin concentrations were increased in obese dogs compared with lean control dogs (Jeusette et al., 2005). In humans, fasting plasma total ghrelin level was negatively correlated with body mass index (Ravussin et al., 2001; Tscho¨p et al., 2001b; Shiiya et al., 2002; Haqq et al., 2003; Purnell et al., 2003; Butler and Bittel, 2007) and body fatness (Ravussin et al., 2001), whereas fasting plasma obestatin level was negatively correlated with body mass index (Guo et al., 2007; Nakahara et al., 2008) and body fatness (Nakahara et al., 2008). However, using a separate measuring method of plasma acyl and des-acyl ghrelin, two independent research groups theorized that plasma total (Barazzoni et al., 2007) and des-acyl ghrelin (Barazzoni et al., 2007; Rodriguez et al., 2009) levels were negatively correlated with body mass index, whereas plasma acyl ghrelin concentration was positively correlated with body mass index (Barazzoni et al., 2007; Rodriguez et al., 2009). Therefore, the assumption that systemic total ghrelin levels reflect acyl ghrelin secretion should be made with caution (Gauna et al., 2007). For instance, fasting plasma total ghrelin (Cummings et al., 2002a; English et al., 2002; Rigamonti et al., 2002; Shiiya et al., 2002; Erdmann et al., 2005; Korner et al., 2005, 2006; le Roux et al., 2005b; Engstro¨m et al., 2007; Guo et al., 2007; Vicennati et al., 2007; Huda et al., 2009; Yang et al., 2009), des-acyl ghrelin (Rodriguez et al., 2009), and obestatin (Guo et al., 2007; Nakahara et al., 2008) concentration were lower in obese than lean subjects, whereas acyl ghrelin concentration was higher in obese persons (Rodriguez et al., 2009). In addition, obese persons showed lower expression of GHS-R in omental adipose tissue (Rodriguez et al., 2009). But another study showed that all ghrelin gene products, including acyl ghrelin, des-acyl ghrelin, and obestatin, were all negatively correlated with body mass index and body fatness (Nakahara et al., 2008). Plasma fasting ghrelin concentration was decreased in obese white persons compared with lean white persons, whereas fasting plasma ghrelin was lower in Pima Indians, a population with a very high prevalence of obesity compared with white persons (Tscho¨p et al., 2001b), indicating that obese subjects possess lower fasting plasma ghrelin levels compared with lean subjects, and different fasting plasma ghrelin

---

**TABLE 6**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Animals Studied</th>
<th>Administration Routes with and without Acting Areas</th>
<th>Effects on Anxiety</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyl ghrelin</td>
<td>Mice</td>
<td>i.c.v. and i.p.</td>
<td>↑ Anxiogenic activities in the elevated plus maze test</td>
<td>Asakawa et al., 2001a</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Rats</td>
<td>i.c.v. and microinjected into hippocampus, amygdala, and dorsal raphe nucleus</td>
<td>↑ Anxiety</td>
<td>Carlini et al., 2002, 2004</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Neonatal chicks</td>
<td>i.c.v.</td>
<td>↑ Anxiety</td>
<td>Carvajal et al., 2009</td>
</tr>
<tr>
<td>Antisense DNA for</td>
<td>Rats</td>
<td>i.c.v.</td>
<td>↑ Anxiolytic effects</td>
<td>Kanehsa et al., 2006</td>
</tr>
<tr>
<td>Acyl ghrelin</td>
<td>Rats</td>
<td>i.c.v.</td>
<td>↑ Memory retention</td>
<td>Carlini et al., 2007b</td>
</tr>
</tbody>
</table>

i.c.v., intracerebroventricular; i.p., intraperitoneal.
levels exist in different racial groups. These results indicate that fasting plasma total ghrelin is down-regulated as a consequence of excess energy or excess energy storage. Plasma total ghrelin fell to a nadir after eating in lean subjects, but obese humans exhibited a blunted postprandial suppression after normal diet or high-fat meals in both Western and Eastern studied populations, suggesting that food failed to suppress this hunger signal in obese persons, which predisposes to hyperphagia and excess weight gain and reinforces obesity (English et al., 2002; Erdmann et al., 2005; le Roux et al., 2005b; Yang et al., 2009). Postprandial total ghrelin level was elevated in black women compared with white women (Brownley et al., 2004), implying that subnormal postprandial ghrelin suppression may account for overweight and obesity in this ethnic group. An intriguing blunting in the nocturnal rise in plasma total ghrelin concentration was found in obese subjects and may be an important hallmark in the biology of obesity (Yildiz et al., 2004). Taken together, the abnormal low fasting total ghrelin level, the lack of postprandial total ghrelin suppression, and the blunted nocturnal rise in plasma total ghrelin concentration in obese subjects may be involved in the pathophysiology of human obesity. These changes may simply reflect a physiologic response to the decrease in caloric need during obesity. The circulating fasting plasma total ghrelin-to-obestatin ratio was found to be positively correlated with body mass index and was higher in obese than normal-weight Eastern people, suggesting a possible involvement of a high preprandial total ghrelin-to-obestatin ratio in the pathophysiology of human obesity (Guo et al., 2007). In contrast, the circulating fasting plasma obestatin concentration was higher in female obese Western people than in control subjects, whereas the fasting plasma total ghrelin-to-obestatin ratio was lower (Vicennati et al., 2007). The discrepancy could come from different sex and ethnic groups being enrolled.

Transgenic mice that overexpressed acyl ghrelin exhibited hyperphagia without altering long-term body weight gain because of a paradoxical increase in energy expenditure (Bewick et al., 2009). These mice with chronic hyperghrelinemia remained responsive to exogenous acyl ghrelin-induced feeding. Another genetic model of mice overexpressing acyl ghrelin showed no increases in food intake or fat mass and no decrease in energy expenditure (Reed et al., 2008). Different gene promoters used could explain the differences. 

Ghrelin-null [ghrelin(−/−)] mice exhibited neither dwarfs nor anorexia as predicted (Sun et al., 2003), implying that ghrelin may not be critically required for viability, growth, and appetite in rodents. In addition, ghrelin-null mice displayed normal response to starvation and diet-induced obesity (Sun et al., 2003). However, a recent study revealed that male ghrelin-knockout mice were protected from the rapid weight gain induced by early exposure to a high-fat diet 3 weeks after weaning (Wortley et al., 2005). This reduced weight gain was linked with decreased adiposity, increased energy expenditure and locomotor activity, and a paradoxical preservation of the GH/IGF-1 axis as the animals aged (Wortley et al., 2005). Another study using GHS-R1a-knockout mice showed that GHS-R1α-null mice ate less food, stored less of their consumed calories, preferentially used fat as an energy substrate, and accumulated less body weight and adiposity than control mice (Zigman et al., 2005). However, another study showed that ghrelin-knockout mice only resisted high-fat diet-induced glucose intolerance but not body weight gain (Dezaki et al., 2006), and yet another study revealed that GHS-R1a-knockout mice exhibited blunted central acyl ghrelin-induced feeding response, obese phenotype, hyperleptinemia, hypoinsulinemia, and hypolipidemia (Egecioglu et al., 2006). On the other hand, three independent research groups demonstrated that transgenic mice overexpressing des-acyl ghrelin in their plasma (or in various tissues) showed small phenotype in terms of linear growth (Ariyasu et al., 2005; Asakawa et al., 2005), lower plasma IGF-I level (Ariyasu et al., 2005), decreased fat mass (Asakawa et al., 2005; Zhang et al., 2008a), decreased food intake and body weight (Asakawa et al., 2005), and resistance to high-fat diet-induced obesity (Zhang et al., 2008a). In contrast, a study using rat insulin II promoter-ghrelin transgenic mice overexpressing des-acyl ghrelin in their plasma revealed that des-acyl ghrelin had influence only on glucose metabolism without altering feeding behavior, body weight, and body fat in these transgenic mice (Iwakura et al., 2005). But a study showed that neither ghrelin- nor GHS-R-knockout mice were resistant to diet-induced obesity (Sun et al., 2008). Collectively, acyl ghrelin-knockout and GHS-R1a-knockout mice (Wortley et al., 2005; Zigman et al., 2005), as well as des-acyl ghrelin-overexpressing mice (Zhang et al., 2008b), are all resistant to high-fat-diet-induced obesity, indicating the indispensable roles for endogenous ghrelin gene products/GHS-R1a signaling system in the metabolic adaptation to nutrient availability and for the development of the full phenotype of diet-induced obesity. Therefore, antagonizing biological actions of acyl ghrelin may reduce food intake and prevent obesity, especially in the face of a metabolically stressful diet. However, ablation of acyl ghrelin only improved the diabetic but not obese phenotype of ob/ob mice (Sun et al., 2006). It is noteworthy that simultaneous deletion of acyl ghrelin and its receptor increased motor activity and energy expenditure in these double-knockout mice, implying the existence of additional as-yet unknown molecular components of the endogenous ghrelin/GHS-R1a system (Pfugler et al., 2008).

Prader-Willi syndrome is the most common and famous prototype of human genetic obesity, involving imprinting disorders of several genes on chromosome 15, and is characterized by severe hyperphagia, GH defi-
ciency, hypogonadism, neonatal hypotonia, dysmorphic features, and cognitive impairment. Marked increased plasma total and acyl ghrelin levels were found in Prader-Willi syndrome, and the elevated ghrelin acted as an orexigenic factor, driving the insatiable appetite and obesity in these patients (Cummings et al., 2002a; DelParigi et al., 2002; Haqq et al., 2003; Paik et al., 2006), whereas plasma des-acyl ghrelin levels remained unchanged compared with obese children who did not have Prader-Willi syndrome (Paik et al., 2006). Fasting plasma obestatin could be unchanged (Park et al., 2007) or elevated (Butler and Bittel, 2007) in subjects with Prader-Willi syndrome. The magnitude of the postprandial total ghrelin suppression was less in patients with Prader-Willi syndrome than in obese and lean subjects (Giménez-Palop et al., 2007).

Fasting gastric acyl ghrelin mRNA expression in mice was increased by a high-fat diet (Asakawa et al., 2003). Lipids suppressed the peripheral ghrelin secretion relatively more weakly than glucose or amino acids in rats (Overduin et al., 2005) and humans (Foster-Schubert et al., 2008), including lean and obese subjects (Yang et al., 2009), whereas dietary fructose attenuated postprandial suppression of total ghrelin (Teff et al., 2004), contributing to the fact that high-fat and high-fructose diets predispose to weight gain. Intravenous administration of acyl ghrelin increased food intake in obese and lean subjects (Druce et al., 2005). However, exogenous acyl ghrelin infusion increased palatability of food in the obese, and obese people were more sensitive to the appetite-stimulating effects of acyl ghrelin than were lean people (Druce et al., 2005), suggesting that inhibition of circulating acyl ghrelin may be a useful therapeutic target in the treatment of obesity. Collectively, in the developed and developing countries (including Western and Eastern societies), humans often consume diets very rich in fat and/or fructose and in overall caloric content even if there is no metabolic need for it. Furthermore, hypertriglyceridemia induced by high-fat diet promotes transport of circulating acyl ghrelin across the blood-brain barrier, which would amplify its orexigenic effect in the brain (Banks et al., 2008). Thus, the inability of their bodies to counteract the actions of acyl ghrelin may be a deteriorating adaptive mechanism, leading to the development of metabolic syndrome and obesity in the modern societies. Therefore, pharmacological inhibition of the action of acyl ghrelin in humans, especially for those people frequently under high-fat and/or high-energy diet, provides a new venue for antiobesity therapy.

Initial studies using antagonism of GHS-R1a or ghrelin’s downstream mediator (i.e., AgRP, via injecting melanotan II into the third ventricle) showed reduced acyl ghrelin- and food deprivation-induced food intake, body weight gain, and food hoarding in mice (Asakawa et al., 2003) and hamsters (Keen-Rhinehart and Bartness, 2007). Another study revealed that small-molecule GHS-R1a antagonists improved glucose tolerance, suppressed appetite, and promoted weight loss in rats (Esler et al., 2007), suggesting promising clinical therapeutic value of GHS-R1a antagonism for controlling the obesity pandemic in developed countries. Two novel GHS-R1a antagonists [JMV 3002 and JMV 2959 (Salomé et al., 2009a)] and one partial agonist [JMV 2810 (Salomé et al., 2009a)] have been developed to show in vivo suppression of central acyl ghrelin- and fasting-induced food intake (at the central nervous system level) in rats and in vitro suppression of acyl ghrelin-induced firing rate of the arcuate nucleus (at the single cell level) (Salomé et al., 2009a). Central treatment with acyl ghrelin for 14 days, compared with vehicle-treated control rats, resulted in increases in body weight, lean mass, fat mass (assessed by dual energy X-ray absorptiometry), dissected white fat pad weight, cumulative food intake, food efficiency, and respiratory exchange ratio, and a decrease of energy expenditure in rats, whereas coadministration of the recently developed GHS-R1a antagonist JMV 2959 blocked the majority of these effects, with the notable exception of acyl ghrelin-induced food intake and food efficiency. The results identified the role of GHS-R1a mediating the long-term effects of acyl ghrelin on fat accumulation, which could be at least partly independent of food intake (Salomé et al., 2009b).

Because the central ghrelin gene products/ GHS-R signaling system has emerged as an important pro-obesity target, antagonism of acyl ghrelin at the central nervous system level is of potential value in the treatment of obesity and clinically related diseases. Recent studies using in vitro-generated biostable RNA-based compounds (i.e., anti-acyl ghrelin Spiegelmer) specifically binding n-octanoyl ghrelin have been successfully invented to inhibit acyl ghrelin-stimulated GHS-R activation (Helming et al., 2004), including in vitro blocking of acyl ghrelin-induced excitation of electrophysiological firing in the medial arcuate nucleus in rats (Becskei et al., 2008) and in vivo suppression of neurostimulatory and orexigenic effects of peripheral acyl ghrelin in rats (Kobelt et al., 2006) and to ameliorate obesity in diet-induced obese mice (Shearman et al., 2006). Other specific monoclonal antibodies, including a high-affinity neutralizing antibody binding acyl ghrelin [i.e., 33A (Lu et al., 2009)] and a catalytic degradation antibody facilitating hydrolysis of the serine octanoate ester moiety of acyl ghrelin (Mayorov et al., 2008), have also been generalized to inhibit in vitro acyl ghrelin-mediated calcium signal and in vivo short-term acyl ghrelin-induced orexigenic effects in mice (Lu et al., 2009), and to maintain greater whole body energy expenditure during fasting and reduce subsequent refueling in mice (Mayorov et al., 2008). Furthermore, vaccination of rats with acyl ghrelin immunonoconjugates resulted in hypophagia and decreases in weight gain and body fat (Zorrilla et al., 2006). Taken together, these findings point out the critical role of acyl ghrelin in body weight regulation and the development of obesity. How-
ever, the anti-acyl ghrelin Spiegelmer did not block neuronal activation of the hypothalamic arcuate nucleus in food-deprived mice (Becskai et al., 2008), whereas long-term administration of 33A did not affect food intake or body weight gain in a mouse model of diet-induced obesity (Lu et al., 2009). Hence, antagonizing the peripheral acyl ghrelin pathway alone may not be sufficient for treating obesity. The sum of other fasting-related signals, such as a drop in glucose, insulin, and leptin concentrations, may play the predominant role in this process. Therefore, further studies using combination therapies that block multiple orexigenic pathways are warranted to provide further insight in better understanding the contributions of acyl ghrelin in overall intake, body weight regulation, and the formation of obesity.

In contrast to conventional pharmacotherapy, bariatric surgery, especially gastric bypass, in which most of the stomach and duodenum are bypassed with the use of a gastrojejunal anastomosis, is the only validated, substantial, sustained, and effective way to provide long-term weight loss and improved lifestyle for patients with morbid obesity (Sjöström et al., 2004). Gastric bypass not only decreases overall mortality compared with conventional treatment (Sjöström et al., 2004) but also demonstrates an advantageous outcome concerning body composition and dietary intake, including an avoidance of fat, compared with vertical banded gastroplasty (Olbers et al., 2006). Plasma total ghrelin level increased after diet control-induced weight loss (Cummings et al., 2002b; Frühbeck et al., 2004b), whereas 24-h plasma total ghrelin concentration was abnormally low (Cummings et al., 2002b; Frühbeck et al., 2004b) or tended to decrease (Korner et al., 2009) after gastric bypass surgery. The elevated plasma total ghrelin level easily induces hunger sensation for those subjects on diet, and thus hyperphagia occurs, often resulting in body weight regain and leading to failure of diet control. Furthermore, the reduction in circulating total ghrelin concentration in patients receiving Roux-en-Y gastric bypass was not determined by an active weight loss or an improved insulin sensitivity but rather depended on the gastric fundus level, which supported the hypothesis that sustained weight loss observed after gastric banding did not depend solely on food restriction (Monteiro et al., 2007). However, restrictive surgery, such as gastric banding, sometimes resulted in increased (Nijhuis et al., 2004; Korner et al., 2009) or unchanged (Hanusch-Enserer et al., 2003) plasma total ghrelin level after operation in humans. In addition, gastric bypass surgery improved human metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease (Mattar et al., 2005; Barker et al., 2006; Klein et al., 2006; Furuya et al., 2007). Moreover, because gastrointestinal malignancies may be associated with obesity, pharmacologic and surgical avenues available for treatment of obesity, including lipase inhibitors and gastric or jejunoileal bypass procedures, may set the stage for subsequent gastrointestinal tract cancer.

In brief summary, obesity is the outcome of the dysregulation of a central network of neuropeptidergic and monoaminergic circuits that provide an interface between genetic background and the environment (Yildiz et al., 2004). Nibbling at ghrelin gene products/GHS-R1a system through medical, surgical, or combination therapy, especially manipulating regulation of GOAT at the gastric fundus level, should be therapeutically relevant to morbid obesity and constitute a strategy for the treatment of overeating and obesity.

B. Anorexia and Cachexia

1. Cancer Anorexia-Cachexia Syndrome. Ghrelin is very attractive because it can attenuate cancer-induced anorexia and cachexia. Acyl ghrelin and des-acyl ghrelin were demonstrated in normal tissues and various tumorous tissues, such as human pituitary adenomas (Kim et al., 2001; Korbonits et al., 2001a,b; Martinez-Fuentes et al., 2006), fetal thyroid and follicular tumors (Volante et al., 2003), adrenocortical tumors (Barzon et al., 2005), medullary thyroid carcinoma cell lines (Kanamoto et al., 2001; Morpurgo et al., 2005), gastric endocrine tumors (Papotti et al., 2001; Rindi et al., 2002; Rayhan et al., 2005), intestinal endocrine tumors (Papotti et al., 2001; Rayhan et al., 2005), gastrointestinal stromal tumors (Ekeblad et al., 2006), pancreatic endocrine tumors (Iwakura et al., 2002; Volante et al., 2002; Ekeblad et al., 2007), the small-cell lung cancer cell line (Cassoni et al., 2006), bronchial neuroendocrine tumor (Arnaldi et al., 2003), prostate neoplasms and prostate cancer cell lines (Jeffery et al., 2002; Cassoni et al., 2004), testicular tumors (Gaytan et al., 2004), breast cancer tissues (Jeffery et al., 2005), and leukemia cell lines (De Vrieze and Delporte, 2007), using either RT-PCR, immunohistochemistry, or in situ hybridization. Moreover, the promoter region of the ghrelin gene was found in human medullary thyroid carcinoma cell line (Nakai et al., 2004), whereas another novel prepro-ghrelin isoform, exon 3-deleted prepro-ghrelin was de-
tected in prostate cancer (Yeh et al., 2005) and breast cancer (Jeffery et al., 2005). On the other hand, GHS-R1a and GHS-R1b, two splice variants of GHS-R, were detected separately and together in human pituitary tumors (Adams et al., 1998; Skinner et al., 1998; Barlier et al., 1999; Korbonits et al., 2001; Kim et al., 2001, 2003a; Martinez-Fuentes et al., 2006), ovarian tumors (Gaytan et al., 2005), astrocytoma (Dixit et al., 2006), adrenocortical tumors (Barzon et al., 2005), gastrointestinal stromal tumors (Ekeblad et al., 2006), pancreatic endocrine tumors (Volante et al., 2002; Ekeblad et al., 2007), the small-cell lung cancer cell line (Cassoni et al., 2006), bronchial neuroendocrine tumor (Arnaldi et al., 2003), prostate neoplasms and prostate cancer cell lines (Jeffery et al., 2002), testicular tumors (Gaytan et al., 2004), breast cancer tissues (Jeffery et al., 2005), and leukemic cell lines (De Vriese and Delporte, 2007). Obestatin has been demonstrated in many endocrine tumors, such as those of the thyroid, parathyroid, stomach, small intestine, appendix, and pancreas (Volante et al., 2009). The expression of obestatin was positively correlated with that of ghrelin in normal and tumorous samples. An immunohistochemical study demonstrated ghrelin immunoreactivity in enterochromaffin-like cells of human stomach, and the authors speculated that gastric enterochromaffin-like cells acquired the capacity to secrete ghrelin early in their hyperplasia-neoplasia sequence (Srivastava et al., 2004). Collectively, these emerging data suggest that ghrelin gene products and their related coupled receptors may play roles (either promoting or inhibiting) in promoting tumor growth via an autocrine/paracrine pathway. However, controversial evidence exists. Some studies reported that ghrelin was not detected in human somatotroph adenomas (Wasko et al., 2006), mucoepidermoid carcinoma of salivary gland (Aydin et al., 2005), esophageal (Mottershead et al., 2007) and gastric (Aydin et al., 2005; Mottershead et al., 2007) adenocarcinoma, and gastrointestinal endocrine tumors with multiple endocrine neoplasia type 1 (Raffel et al., 2005). The authors indicated that an infiltrating adenocarcinoma could decrease ghrelin production and disrupt local paracrine mechanisms by replacing normal gastric mucosa (Mottershead et al., 2007). They also speculated that the absence of ghrelin in these tumors may be important in loss of appetite in these patients. The reasons for these discrepancies need further evaluation.

In addition to these autocrine/paracrine effects, ghrelin could exert anabolic actions in cancer anorexia-cachexia through an endocrine mechanism. Two new tumor entities of stomach and pancreas, gastric ghrelinoma (Tsolakis et al., 2004) and pancreatic ghrelinoma (Corbetta et al., 2003), with hypersecretion of ghrelin into the blood circulation, were identified and characterized. Consistent data from two independent research groups revealed that serum total and acyl ghrelin remained unaltered in patients with prostate cancer (Mungan et al., 2008; Bertaccini et al., 2009), implying that insufficient secretion of ghrelin into serum could be responsible. Plasma fasting ghrelin levels were reported to be unchanged in human medullary thyroid carcinomas (Morpurgio et al., 2005), gastric endocrine tumors (Tsolakis et al., 2008), gastric cancer (An et al., 2007; Huang et al., 2007), colorectal cancer (Huang et al., 2007), pancreatic endocrine tumors (Ekeblad et al., 2007), and lung cancer (Shimizu et al., 2003a). Some studies indicated that circulating ghrelin level was decreased in patients with gastric cancer (Isomoto et al., 2007) and colorectal cancer (D’Onghia et al., 2007). Plasma ghrelin level could be increased, unchanged, or decreased in patients with hepatocellular carcinoma (Tacke et al., 2003; Ataseven et al., 2006; Lin and Yin, 2007). The circulating ghrelin level was negatively correlated with tumor staging and lost negative correlation with body mass index in colorectal cancer (D’Onghia et al., 2007), whereas a strong inverse correlation between ghrelin level and α-fetoprotein was observed in hepatocellular carcinoma (Tacke et al., 2003), suggesting that additional studies are necessary to ascertain the potential role of ghrelin as a predictive and prognostic biomarker in these patients. It is noteworthy that plasma ghrelin level was increased in lung cancer patients with cachexia than without cachexia (Shimizu et al., 2003a; Karapanagiotou et al., 2009), indicating a compensatory mechanism under catabolic-anabolic imbalance in patients with cachexia. Elevated serum ghrelin was also found in patients with metastatic neuroendocrine tumors in liver and was positively correlated with body mass index (Wang et al., 2007). Ghrelin could be coreleased from neuroendocrine tumors and exert an orexigenic effect in these patients to maintain body mass index despite widely disseminated disease. Furthermore, elevated serum ghrelin levels and decreased serum leptin levels were found in female patients with breast and colon cancer who had cachexia (Wolf et al., 2006). Different cancers causing different rates of body weight loss could explain these differences. Further studies showed that acyl ghrelin level and the acyl-to-total ghrelin ratio was increased in subjects with cancer-induced cachexia compared with cancer and noncancer controls (Garcia et al., 2005). However, appetite score was not increased in these subjects with cachexia despite elevated ghrelin, suggesting a state of ghrelin resistance. We speculate that GOAT was up-regulated or des-acylation became slower in these patients with cachexia, because the acyl-to-total ghrelin ratio was increased. High rather than low serum ghrelin was surprisingly reported to be associated with protection against esophageal adenocarcinoma among overweight subjects (de Martel et al., 2007). This could come from anti-inflammatory effect of ghrelin, because ghrelin was demonstrated to have an inhibitory effect on Barrett’s carcinogenesis by its anti-inflammatory actions (Konturek et al., 2008). Cachexia has been described as a
GH-resistant state with high GH levels but low IGF-I (Crown et al., 2002). Taken together, cancer cachexia should be a status with both GH and ghrelin resistance, and acyl ghrelin should play a role in signaling and reversing states of energy insufficiency under these circumstances. Future prospective studies using state-of-art techniques to separately measure acyl ghrelin, des-acyl ghrelin, and obestatin are urgently demanded to clarify the differential roles of ghrelin gene products in patients with cancer anorexia and cachexia.

There are few current treatment options for cancer anorexia-cachexia, whereas acyl ghrelin agonist and melanocortin-receptor antagonists are two kinds of promising drugs among them (Bossola et al., 2006). Plasma total ghrelin concentration was increased and leptin concentration was decreased in cachectic nude mice inoculated with two different human melanoma cells (Hanada et al., 2003, 2004) and normal mice implanted with sarcoma (Wang et al., 2006). Ghrelin biosynthesis and secretion were up-regulated with the progression of cachexia, and exogenous administration efficiently counteracted body weight loss in these cachectic mice (Hanada et al., 2003, 2004), suggesting that elevated ghrelin may represent a compensatory mechanism and have a therapeutic ability to ameliorate cancer cachexia. However, a recent study indicated that continuous intravenous infusion of rat acyl ghrelin failed to stimulate feeding in tumor-bearing rats, although acyl ghrelin-infused tumor-bearing rats exhibited elevated hypothalamic NPY and reduced hypothalamic POMC message (Chance et al., 2008). Different ways of drug administration (pulsatile versus continuous dosing) and different species (mice versus rats) could explain the discrepancies, implying that continuous acyl ghrelin infusion might not be an effective treatment for cancer anorexia. Another study using a rat model of cancer cachexia, implanted with methylcholanthrene sarcoma, showed that exogenous injection of human acyl ghrelin and a synthetic acyl ghrelin analog BIM-28131 (DeBoer et al., 2007; Deboer et al., 2008) efficiently improved food intake and lean body mass in these tumor-bearing rats and accompanied increased hypothalamic expression of orexigenic genes and decreased expression of the transcript of interleukin-1 receptor (DeBoer et al., 2007). Hence, acyl ghrelin and a synthetic ghrelin analog improved cancer anorexia and cachexia through appetite-regulating and anti-inflammatory mechanisms. Wisse et al. (2001) demonstrated that intracerebroventricular injection of melanocortin receptor antagonist SHU9119 completely reversed cancer anorexia in tumor-bearing rats, whereas the orexigenic effects of intracerebroventricular acyl ghrelin and NPY were blunted relative to those in control rats. The orexigenic effect of exogenous acyl ghrelin was partially blunted in tumor-bearing mice compared with normal mice (Wang et al., 2006), suggesting the appearance of acyl ghrelin resistance. Moreover, GHS-R1a expression in the hypothalamus of the cachectic mice was up-regulated. Therefore, other factors downstream of the ghrelin-GHS-R1a system should be more important than acyl ghrelin for the pathogenesis of cancer anorexia-cachexia. Taken together, all these implied greater value of melanocortin receptor antagonists in the treatment of cancer anorexia-cachexia syndrome.

In a pilot human trial, intravenous infusion of exogenous human acyl ghrelin successfully stimulated energy intake in seven patients with cancer who had impaired appetite (Neary et al., 2004). A randomized, placebo-controlled, double-blind, double-crossover study confirmed that intravenous administration of human acyl ghrelin was safe and well tolerated in patients with advanced incurable cancer and anorexia/cachexia (Strasser et al., 2008). A phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers demonstrated that RC-1291 (Garcia and Polvino, 2007), a novel, orally available ghrelin mimetic and GHS, was well tolerated and effective in promoting weight gain with few adverse events (Garcia and Polvino, 2007). The results give hope for the treatment of cancer anorexia-cachexia. Therefore, early detection of cancer-associated anorexia-cachexia syndrome followed by exogenous administration of acyl ghrelin may present an efficient option of combating this deleterious disease. However, acyl ghrelin promoted pancreatic adenocarcinoma cellular proliferation and invasiveness and astrocytoma motility in cell lines (Duxbury et al., 2003; Dixit et al., 2006). A novel association between acyl ghrelin and colorectal cancer has been reported. Ghrelin expression was found to be enhanced in malignant colorectal cells, and it promoted colorectal malignancy by advancing tumor stage through an autocrine/paracrine mechanism (Waseem et al., 2008). Therefore, it is extremely important to determine whether ghrelin is truly carcinogenic or protective against malignancy. We strongly believe that acyl ghrelin will be a new therapeutic target for cancer-related anorexia-cachexia syndrome and/or a new prognostic factor in the next decade.

2. Noncancerous Anorexia-Cachexia.

a. Psychogenic: anorexia nervosa. Among psychiatric disorders, anorexia nervosa is a highly morbid pathologic condition with high mortality. These patients experience hunger, but they avoid eating by intense fear of overconsumption and being overweight. Anorexia nervosa often affects young women under 25 years old, and is characterized by weight loss, amenorrhea, and behavioral changes. In addition to marked loss of body weight, this abnormal feeding behavior also leads to metabolic disturbances and is usually life-threatening without proper treatment. Therefore, elucidating the underlying neuroendocrine mechanisms of anorexia nervosa is pivotal for the pharmacotherapy of this disease. In female patients with anorexia nervosa, morning fasting total ghrelin level was significantly higher than those in control (Ariyasu et al., 2001; Nakai et al., 2003; Tolle et al., 2003; Broglio et al., 2004a; Tanaka et al., 2004; Hotta et
reported that plasma obestatin, acyl ghrelin, and des-acyl ghrelin levels were significantly higher in patients with the restrictive type of anorexia nervosa (Harada et al., 2008; Nakahara et al., 2008). All three ghrelin gene products decreased after the oral glucose tolerance test in patient and control groups. The fact that fasting plasma des-acyl ghrelin level was higher in patients with anorexia nervosa and decreased after the oral glucose tolerance test in both patient and control groups, suggesting either a decrease in acylation or an increase in desacylation of ghrelin in anorexia nervosa. Postprandial decline of plasma acyl ghrelin response to the oral glucose tolerance test was blunted in these female patients with anorexia nervosa compared with control subjects (Harada et al., 2008). These imply that ghrelin gene products may serve as markers reflecting both short- and long-term changes of the nutritional state in patients with the restrictive type of anorexia nervosa. However, exogenously intravenous infusion of human acyl ghrelin did not affect GH responses and appetite (in terms of hunger) in patients with anorexia nervosa compared with constitutionally thin subjects but tended to increase sleepiness only in patients with anorexia nervosa (Miljic et al., 2006). In addition, exogenously intravenous infusion of human acyl ghrelin had no effect on glucose metabolism and insulin secretion in patients with anorexia nervosa (Miljic et al., 2007). They concluded that exogenous acyl ghrelin supplementation was unlikely to be effective as a single appetite-stimulatory agent in patients with anorexia nervosa (Miljic et al., 2006). In an independent study, patients with anorexia nervosa exhibited specific reduction in the GH response to exogenous acyl ghrelin administration, despite the hyper-responsiveness to GHRH injection (Broglio et al., 2004a). In contrast, six of nine patients experienced hunger after acyl ghrelin administration (Broglio et al., 2004a). These reflect “desensitization” of the GHS-R1a induced by the chronic elevation of ghrelin level in this pathological condition, and ghrelin itself is unlikely to play a causal role in anorexia nervosa. Further studies may be warranted to investigate the pathogenesis and how to overcome ghrelin resistance in patients with anorexia nervosa for future treatment. Before these, additional studies conducting simultaneous measurement of acyl ghrelin, des-acyl ghrelin, and obestatin should provide a better understanding of metabolic responses to ghrelin in anorexia nervosa.

Future studies are necessary to explore putative molecular mechanisms underlying ghrelin resistance, such as a possible impairment of intracellular GHS-R1a signaling in pathophysiological states presenting with cachexia. On the other hand, plasma ghrelin levels are higher in patients with bulimia nervosa (Tanaka et al., 2002; Kojima et al., 2005), although the body mass index is similar to that of control subjects (Tanaka et al., 2002). Lack of a leptin response to food ingestion was observed in both bulimic and healthy women, compatible with leptin acting as a long-term rather than short-
term modulator of eating behavior (Monteleone et al., 2003). Significantly blunted increase of circulating PYY (Kojima et al., 2005; Monteleone et al., 2005) and reduced suppression of plasma ghrelin (Monteleone et al., 2003, 2005; Kojima et al., 2005) after the test meal were demonstrated in bulimic and healthy women, whereas plasma ghrelin suppression after the meal was significantly correlated with plasma PYY increase in the patients (Monteleone et al., 2005). No significant differences emerged in food-induced plasma insulin and glucose changes between bulimic and healthy women (Monteleone et al., 2005). Moreover, for both patients with anorexia nervosa and those with bulimia nervosa with habitual binge/purge behavior, there were significant correlations among plasma ghrelin values, frequencies of binge/purge cycles and serum amylase values, whereas in bulimia nervosa with nonpurging type, there were no significant correlations among plasma ghrelin values, frequencies of binge-eating episodes and serum amylase values (Tanaka et al., 2003). These results indicated that habitual binge/purge cycles with vomiting may have a greater influence on fasting plasma ghrelin concentration in binge eating behavior, and a gut-hypothalamic pathway involving peripheral signals, especially ghrelin, may be involved in the pathophysiology of bulimia nervosa. However, normal endocrine and metabolic responses to exogenous ghrelin administration were observed patients with purging bulimia nervosa and healthy women (Fassino et al., 2005). A further study revealed that circulating ghrelin increased after modified sham feeding in both groups, with patients with bulimia nervosa exhibiting a greater ghrelin increase that positively correlated with the patients' weekly frequency of binge-purging (Monteleone et al., 2009). Finally, ghrelin concentrations and cardiac vagal tone were decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa (Tanaka et al., 2006).

b. Nonpsychogenic: chronic heart failure, chronic obstructive pulmonary disease, liver cirrhosis, and chronic kidney disease.

d. Chronic heart failure. Patients with end-stage chronic heart failure (CHF) are characterized by dysfunction and remodeling of left ventricle and cardiac cachexia (including weight loss and muscle wasting). It is noteworthy that cardiac cachexia is a strong independent risk factor for morbidity and mortality in patients with CHF. Plasma total ghrelin level was determined in a Japanese population (Nagaya et al., 2001b). Plasma total ghrelin level did not differ between patients with CHF and healthy subjects. However, plasma total ghrelin level was higher in patients with CHF and cachexia (defined as those with documented nonedematous and nonintentional weight loss of >7.5% of the previous normal nonedematous weight over a period of at least 6 months) than in those without cachexia. Moreover, circulating GH, TNF-α, norepinephrine, and angiotensin II levels were also significantly higher in patients with CHF and cachexia. It is noteworthy that the elevated plasma total ghrelin was associated with a decrease in body mass index (Nagaya et al., 2001a). The elevated plasma total ghrelin level may represent a compensatory mechanism in cachectic patients with CHF. However, some studies indicated that plasma ghrelin level remained unchanged, whereas plasma adiponectin level was increased irrespective of body mass index in cachectic patients with CHF compared with healthy control subjects (Araújo et al., 2009). In a rat model with doxorubicin-induced heart failure, endogenous plasma total ghrelin level was increased compared with control subjects (Xu et al., 2008). The increased endogenous plasma total ghrelin concentration was positively correlated with cardiac output and high-energy phosphates, suggesting that the increased endogenous plasma total ghrelin level could represent a compensatory self-protective effect by improving cardiac function and retaining myocardial energy reserve in the rats with doxorubicin-induced heart failure. Acyl ghrelin elicits stimulation of feeding (Chen et al., 2005b) and adiposity (Tscho¨p et al., 2000). Therefore, acyl ghrelin may serve as a rational drug target for ameliorating anorexia, cachexia, and cardiovascular dysfunction in the treatment of CHF. To date, the role of obestatin in CHF remains uninvestigated.

In patients with CHF, short-term intravenous infusion of human acyl ghrelin decreased mean arterial pressure and systemic vascular resistance, increased cardiac index and stroke volume index, and elicited GH, prolactin, adrenocorticotropic, cortisol, and epinephrine secretion but had no renal effects (no change in urine volume, urinary sodium excretion, and creatinine clearance) (Nagaya et al., 2001c). All data obtained from short-term injection of acyl ghrelin suggest that acyl ghrelin may have beneficial effects on CHF.

Controversial results exist regarding long-term administration of acyl ghrelin in the treatment of rat models with CHF. In rats with CHF induced by ligation of the left coronary artery, 3-week intermittent subcutaneous administration (twice a day) of acyl ghrelin improved left ventricular dysfunction and attenuated the development of cardiac cachexia (Nagaya et al., 2001d). Serum GH and IGF-1 levels were higher in both CHF and sham-operated rats treated with acyl ghrelin than in sham-operated rats given with placebo. Rats with CHF exhibited impairment of body weight gain and a significant decrease in the muscle/bone ratio (gastrocnemius muscle weight/tibial length). Long-term injection of acyl ghrelin promoted body weight gain in sham-operated rats and also restored the impaired increase of body weight in rats with CHF. In addition, acyl ghrelin treatment partially restored the decrease in the muscle/bone ratio. In addition, long-term administration of acyl ghrelin improved left ventricular dysfunction, as indicated by increases in cardiac output and stroke volume,
and attenuated the development of left ventricular remodeling, as shown by an increase in posterior wall thickness, inhibition of progressive left ventricular enlargement, and in turn, a reduce in left ventricular wall stress (Nagaya et al., 2001d). However, 1-week intermittent subcutaneous administration (once a day) of acyl ghrelin indicated that acyl ghrelin played only a minor role in controlling rat cardiac function (Torsello et al., 2003). The other rat model with CHF induced by ligation of the left coronary artery revealed that neither 2-week continuous infusion by intravenous pump nor 4-week intermittent subcutaneous injection (three times a day) of acyl ghrelin affected cardiac function (Akashi et al., 2009). However, acyl ghrelin treatment increased body weight, lean mass, and fat mass in rats with CHF. The data indicated that long-term administration of acyl ghrelin did not improve cardiac function, regardless of the application route, but inhibited the development of cachectic status in rats with CHF (Akashi et al., 2009). In a human trial, repeated intravenous administration of human acyl ghrelin (twice a day) for 3 weeks significantly increased left ventricular ejection fraction, decreased left ventricular end-systolic volume, increased peak workload and peak oxygen consumption during exercise, and improved muscle wasting in cachectic patients with CHF (Nagaya et al., 2004). Acyl ghrelin treatment also increased food intake score and decreased plasma norepinephrine, epinephrine, and brain natriuretic peptide levels in cachectic patients with CHF (Nagaya et al., 2004). To date, few therapies other than ghrelin have been shown to be beneficial in cardiac cachexia. Taken together, these data indicate that administration of acyl ghrelin may be a novel therapeutic approach for the treatment of CHF. Further studies may investigate the plasma ghrelin changes in patients with CHF before and after percutaneous transluminal coronary angioplasty or heart transplantation and those in cancer patients with doxorubicin-induced heart failure.

**ii. Chronic obstructive pulmonary disease.** In Asian patients with chronic obstructive pulmonary disease (COPD), plasma ghrelin level was found to be higher in underweight patients (BMI <20 kg/m²) than in normal weight patients (BMI ≥20 kg/m²) and healthy subjects (Itoh et al., 2004; Ying et al., 2008). Serum concentrations of inflammatory markers, such as TNF-α (Itoh et al., 2004; Luo et al., 2005; Ying et al., 2008), interleukin-6 (Itoh et al., 2004; Ying et al., 2008), and norepinephrine (Itoh et al., 2004), were higher in underweight patients than those in normal weight patients and control subjects. In contrast, the other study reported that only serum high sensitivity C-reactive protein, interleukin-6, and interleukin-8, but not TNF-α, were elevated in patients with COPD compared with control subjects (Piehl-Aulin et al., 2009). The elevation of plasma ghrelin in underweight patients with COPD may reflect the negative energy balance, because plasma ghrelin was negatively correlated with body mass index (Itoh et al., 2004; Ying et al., 2008) and positively correlated with catabolic factors, such as circulating TNF-α (Itoh et al., 2004; Ying et al., 2008) and norepinephrine (Itoh et al., 2004). Insulin concentration was lower in underweight patients than that in normal-weight patients with COPD and healthy control subjects (Itoh et al., 2004; Ying et al., 2008), whereas IGF-1 concentration was reported to be either increased or decreased in patients with COPD (Itoh et al., 2004; Piehl-Aulin et al., 2009). Furthermore, plasma ghrelin level was positively correlated with percentage of predicted residual volume and residual volume-to-total lung capacity ratio (Itoh et al., 2004) and negatively correlated with forced expiratory volume in 1 s (Ying et al., 2008). The elevation of plasma ghrelin level in these underweight patients is highly linked with a cachectic state and abnormality of pulmonary function (Itoh et al., 2004; Ying et al., 2008). Cachexia is an independent risk factor for mortality in COPD. Thus, pulmonary cachexia should be a therapeutic target in the treatment of COPD. Hence, supplement with exogenous acyl ghrelin may play some roles in ameliorating pulmonary cachexia and abnormal pulmonary functional capacity in underweight patients with COPD. On the other hand, contradictory results also exist. Plasma ghrelin levels were reported to be lower (Luo et al., 2005) or to remain unchanged (Piehl-Aulin et al., 2009) in patients with COPD, whereas plasma leptin levels were either decreased (Luo et al., 2005) or unchanged (Piehl-Aulin et al., 2009). These discrepancies probably result from differences in studied subjects included and distinct ghrelin measuring methods.

In the follow-up study, repeated intravenous administration of human acyl ghrelin (twice a day) in seven cachectic patients with COPD for 3 weeks significantly increased appetite, body weight, lean body mass, handgrip strength, and maximal inspiratory pressure (Nagaya et al., 2005). In addition, Karnofsky performance status score and the distance walked in 6 min were improved after 3-week therapy of acyl ghrelin injection. Exogenous acyl ghrelin treatment also attenuated the exaggerated sympathetic nerve activity, as indicated by a marked decrease in plasma norepinephrine level (Nagaya et al., 2005). These preliminary results imply that the optimistic of exogenous acyl ghrelin pharmacotherapy in the improvement of body composition, muscle wasting, functional capacity, and amelioration of augmented sympathetic nerve activity in cachectic patients with COPD. However, another prospective study in another ethnic group recruiting a larger patient population with longer treatment period is demanded to validate the efficacy and safety for the treatment of exogenous acyl ghrelin using pharmacologic dose in these patients. To date, the role of obestatin in COPD remains uninvestigated.

**iii. Liver cirrhosis.** Malnutrition is very common in patients with liver cirrhosis, and the prevalence is reported as high as 80% depending on the severity of liver
disease. Cirrhotic patients often develop anorexia and subsequently exhibit body weight and muscle loss. Because ghrelin is one of the key hormones in modulating feeding behavior and calorie status, biological actions of ghrelin may be highly linked with protein-energy malnutrition in patients with cirrhosis.

On the other hand, patients with liver cirrhosis had a lower energy intake, higher resting energy expenditure (Kalaitzakis et al., 2007), higher fasting sugar (Kalaitzakis et al., 2007, 2009) and leptin levels (Breidert et al., 2004; Ataseven et al., 2006; Kalaitzakis et al., 2007, 2009), and higher insulin resistance (Kalaitzakis et al., 2007, 2009). Plasma fasting total ghrelin levels were found to be either unchanged (Marchesini et al., 2004; Kalaitzakis et al., 2007, 2009), elevated (Tacke et al., 2003; Ataseven et al., 2006), or decreased (Breidert et al., 2004; Diz-Lois et al., 2009) in patients with cirrhosis compared with control subjects. Separate measurement of acyl and des-acyl ghrelin could solve the discrepancy. Plasma postprandial total ghrelin level was reduced in patients with liver cirrhosis (Kalaitzakis et al., 2007, 2009; Diz-Lois et al., 2009). High plasma fasting total ghrelin level was found to be associated with a low calorie intake, the anorexia score, and adjustment of body mass index in patients with cirrhosis (Marchesini et al., 2004). Therefore, in the presence of anorexia, hyperghrelinemia may indicate a compensatory mechanism trying to stimulate food intake, which is nonetheless ineffective in the physiological range in liver cirrhosis. In patients with cirrhosis and hyperghrelinemia, plasma GH level was increased (Diz-Lois et al., 2009), whereas plasma IGF-1 level was decreased (Tacke et al., 2003; Diz-Lois et al., 2009), which also suggests GH resistance in these patients. In patients with liver cirrhosis, plasma fasting total ghrelin level increased in Child class C cirrhosis, linked with complications of chronic liver disease, such as previous gastrointestinal bleeding, ascites, and hepatic encephalopathy (Tacke et al., 2003), and was negatively correlated with plasma leptin (Ataseven et al., 2006) and GH levels (Diz-Lois et al., 2009) and positively correlated with plasma TNF-α level (Ataseven et al., 2006). The reduced postprandial total ghrelin concentration was reported to be associated with delayed gastric emptying in patients with cirrhosis (Kalaitzakis et al., 2009). On the other hand, plasma fasting des-acyl ghrelin, known as another ghrelin gene product, was slightly but not significantly elevated in patients with liver cirrhosis (Takahashi et al., 2006a). Des-acyl ghrelin level was negatively correlated with plasma leptin level, body mass index, arm muscular circumference, triceps skinfold thickness, the substrate oxidation rates of glucose and fat as well as nonprotein respiratory quotients. These data suggest that plasma fasting des-acyl ghrelin level may be a useful indicator reflecting malnutrition in patients with cirrhosis. To date, the role of obestatin in liver cirrhosis remains uninvestigated.

In a rat model with hepatic injury induced by bile duct ligation, exogenously injected acyl ghrelin reversed all oxidant responses, restored impaired liver function, elevated serum cytokines, and elevated total histological scores of liver injury (Içeri et al., 2008). Further clinical trials using ghrelin administration for its orexigenic, anabolic, and anti-inflammatory properties in pharmacological amounts to ameliorate anorexia-cachexia syndromes in patients with liver cirrhosis are strongly required.

iv. Chronic kidney disease. Anorexia is present in approximately 33 to 40% of patients receiving hemodialysis and has detrimental effects on nutritional status, quality of life, and survival (Bossola et al., 2006; Mucs caritoli et al., 2007). The role of ghrelin and melanocortin-receptor antagonists (Bossola et al., 2006) seems promising. Therefore, it is interesting to investigate the role of ghrelin in patients with chronic kidney disease (CKD) or end-stage renal disease. The kidney is the primary site of ghrelin clearance, although ghrelin clearance is reduced at the late stage of rat sepsis (Wu et al., 2003). Plasma fasting total (Rodriguez Ayala et al., 2004; Jarkovská et al., 2005a, 2005b; Tentolouris et al., 2005; Iglesias et al., 2006; Chang et al., 2005; Barazzoni et al., 2008; Arbeiter et al., 2009), acyl (Yoshimoto et al., 2002; Pérez-Fontán et al., 2004; Chang et al., 2005; Jarkovská et al., 2005a; Barazzoni et al., 2008), and des-acyl (Yoshimoto et al., 2002; Mucs caritoli et al., 2007) ghrelin levels were all elevated in patients with CKD, regardless of the modality of therapy using either hemodialysis or peritoneal dialysis. Plasma GH and IGF-1 levels were also increased, but neither of them was shown to be associated with the elevated plasma ghrelin level in these patients (Jarkovská et al., 2005a). However, the other two studies reported that the plasma GH level was positively correlated with the elevated plasma ghrelin level (Yoshimoto et al., 2002; Iglesias et al., 2006). Age was demonstrated negatively correlated with plasma fasting acyl ghrelin in patients with CKD (Pérez-Fontán et al., 2004). Plasma concentrations of inflammatory markers such as leptin (Jarkovská et al., 2005b) and C-reactive protein (Barazzoni et al., 2008) were also increased in patients with CKD. Plasma total ghrelin, acyl ghrelin, and des-acyl ghrelin levels were effectively removed from the blood after a single course of hemodialysis in patients with CKD (Yoshimoto et al., 2002; Pérez-Fontán et al., 2004). Plasma ghrelin level was negatively correlated with glomerular filtration rate (Arbeiter et al., 2009) and serum creatinine clearance (Ueno et al., 2007) in subjects with and without CKD. Nevertheless, contradictory results showed that only peritoneal dialysis, instead of hemodialysis, were accompanied by a striking decrement of plasma total ghrelin concentration in patients with CKD (Iglesias et al., 2006). In addition, 12-month treatment with peritoneal dialysis decreased the elevated plasma total ghrelin level and increased body fat in patients with CKD (Ro-
driguez Ayala et al., 2004). Taken together, all evidence indicates that the kidney is an important site for clearance and/or degradation of ghrelin and that ghrelin accumulates in patients with CKD.

Self-reports of appetite level have been validated as a useful predictor of outcome in patients with CKD undergoing hemodialysis (Carrero et al., 2007). Anorexia, instead of hyperphagia, was found in patients receiving hemodialysis with a higher area-under-the-curve of plasma acyl ghrelin level. These suggest there is ghrelin resistance (central, peripheral, or both) in patients with CKD. Hyperghrelinemia in uremic patients with anorexia may be a compensatory pathway rather than a causative factor in mediating uremic anorexia and cachexia. Moreover, hyperghrelinemia and poor appetite were found in pediatric patients with CKD, whereas plasma total ghrelin level returned to normal and appetite was improved after renal transplantation (Arbeiter et al., 2009). On the other side, plasma des-acyl ghrelin level was higher in anorexic than nonanorexic patients with CKD undergoing hemodialysis (Muscitoli et al., 2007), suggesting that des-acyl ghrelin might play a pathogenic role in poor appetite of patients with CKD. A recent report indicated that resting energy expenditure was similar in patients with maintenance hemodialysis and healthy control subjects (Barazzoni et al., 2008). This implies that anorexia plays a more important role than energy expenditure in mediating CKD-related cachexia, which worsens the prognosis in patients with CKD. Hence, additional prospective studies with a larger sample size and a longer observational period are warranted to further clarify the causative role of des-acyl ghrelin in uremia-related anorexia. To date, the role of obestatin in CKD remains uninvestigated.

Recently, a rat model with CKD induced by five sixths nephrectomy resulted in decreased food intake and lean body mass, whereas treatment with acyl ghrelin and small-molecule agonists of GHS-R1a, such as BIM-28125 (Deboer et al., 2008) and BIM-28131, successfully improved them, in part mediated via a decrease in muscle actinomycin degradation (Deboer et al., 2008). Hypothalamic NPY, AgRP, and POMC gene expression was unchanged, whereas prohormone convertase-2 level in the hypothalamus was increased in rats with CKD, which resulted an increase in the processing of POMC and subsequently an increase in the secretion of downstream anorexigenic hormones leading to hypophagia, such as α-melanocyte stimulating hormone. Combined pro-inflammatory cytokines were elevated in these rats with CKD, whereas acyl ghrelin and small-molecule ghrelin analogs blocked these elevations. In addition, treatment with acyl ghrelin and small-molecule ghrelin analogs down-regulated interleukin-1 receptor I expression in the brainstem in rats with CKD, which exhibited the anti-inflammatory effect of ghrelin and agonists of GHS-R1a. Thus, acyl ghrelin treatment caused increasing hypothalamic feeding center outflow and an overall decrease in circulating cytokines to ameliorate cachexia induced by CKD. All together, these data highlight the potential clinical application of small-molecule agonists of GHS-R1a that have a longer half-life and oral bioavailability in future therapeutic use in human CKD. However, another similar study revealed that exogenously injected acyl ghrelin transiently stimulated appetite in young rats with CKD but did not increase daily food intake and improve growth (Alvarez-Garcia et al., 2007). In a human randomized, placebo-controlled trial, subcutaneous single-dose acyl ghrelin administration enhanced short-term food intake in patients receiving dialysis with mild to moderate malnutrition (Wynne et al., 2005). Longer-term studies in humans with CKD are required. Finally, further investigation is urgently needed to better understand the pathogenic mechanisms of CKD-related anorexia-cachexia syndrome and to determine whether amelioration of anorexia and improvement of food intake would result in a long-term benefit in terms of improved quality of life and reduced morbidity and mortality in patients with CKD. A recent study revealed that acyl ghrelin administration in 12 malnourished patients receiving dialysis increased ghrelin levels in circulation, modestly reduced blood pressure for up to 2 h, immediately and significantly increased appetite, and had an increase in energy intake, noted at the first study meal; this effect persisted throughout the week without altering energy expenditure (Ashby et al., 2009). Because malnutrition is a common complication in patients receiving dialysis and carries poor prognosis, direct manipulation of appetite with acyl ghrelin or its analogs represents an attractive and promising therapeutic strategy for this difficult clinical problem. All these efforts provide us useful clues for the potential development of more effective preventive and therapeutic interventions in human CKD.

XII. Therapeutic Approaches to Affecting the Ghrelin System: Endogenous Ghrelin Gene Products, Growth Hormone Secretagogue Receptor 1a, and Ghrelin O-acyltransferase

Pharmacological approaches using affecting endogenous acyl ghrelin and GHS-R1a provide us new strategies for the treatment of obesity and metabolic disorders, because acyl ghrelin possess appetite-stimulating and adipogenetic effects. Central administration of the GHS-R1a antagonist JMV 2959 is promising. Central injection of JMV 2959 abolished fat accumulation without altering acyl ghrelin-induced food intake in rats (Salomé et al., 2009b). However, the primary barrier for JMV 2959 is its administration route, and the effects of peripheral application of JMV 2959 need to be determined. Orally available GHS-R1a antagonists, such as quinazolinone (Rudolph et al., 2007), to promote long-term body weight loss and improve glucose homeostasis, are underdeveloped for the treatment of obesity and
diabetes. In addition to affecting acyl ghrelin and GHS-R1a, gastric electrical stimulation could be another option in the treatment of obesity. Acyl ghrelin induced antral contractions and increased food intake in dogs, whereas gastric electrical stimulation was capable of blocking these excitatory effects of acyl ghrelin (Yin and Chen, 2006). These findings suggest that gastric electrical stimulation may inhibit the resistant effect of acyl ghrelin on weight loss. Finally, diet is an important but easily overlooked factor in our treatment of obesity and metabolic syndrome.

In constrast, analogs of acyl ghrelin or GHS-R1a agonists could combat human anorexia-cachexia such as cancerous and noncancerous states. Acyl ghrelin replacement therapy may alleviate weight loss associated with gastrectomy. Activation of the acyl ghrelin/GHS-R1a system is able to restore the normal feeding pattern and energy balance in the elderly and in cancer patients with impaired appetite. Oral MK-677 increased fat-free mass in human elderly (Nass et al., 2008). In addition, the small-molecule GHS-R1a agonist BIM-28131 and the orally available RC-1291 are very promising. Moreover, traditional herb drugs containing acyl ghrelin mimetics, such as Rikkunshito (or TJ-43) (Takeda et al., 2008; Fujitsuka et al., 2009), which stimulates the release of acyl ghrelin via blockade of serotonin mechanism, are alternatives for analogs of acyl ghrelin or GHS-R1a agonists in the treatment of human anorexia-cachexia.

The nonpeptidergic ghrelin receptor agonists [GSK894490A (Atcha et al., 2009) and CP-464709-18] readily crossed the blood-brain barrier and significantly improved performance in the novel object recognition and modified water maze tests in rats (Atcha et al., 2009). Central obestatin has sleep-promoting and memory-enhancing effects. Disturbance of sleep predisposes to the development of obesity. These observations reveal endogenous functions of ghrelin gene products that link metabolic control with higher brain functions and suggest novel therapeutic strategies to enhance learning and memory processes. Besides improving life quality and maintaining independence, GHS-R1a agonists show potential as interventional agents against aging (Smith et al., 2007). The primary barrier is still the administration route of the developed drugs.

The ability of acyl ghrelin to promote gastrointestinal motility makes it feasible to treat delayed gastrointestinal transit in various pathological conditions. Analogs of acyl ghrelin or stimulators on GHS-R1a may represent new classes of prokinetic agents, such as TZP-101, in future treatments for patients with gastroparesis of either diabetic (Murray et al., 2005; Ejskjaer et al., 2009), neurogenic (Binn et al., 2006), idiopathic (Tack et al., 2005), or symptomatic (Wargin et al., 2009) origin, as well as postoperative ileus (Lasseter et al., 2008). Furthermore, ipamorelin has clinical implication in the treatment of patients with postoperative anorexia and body weight loss (Venkova et al., 2009). The emerging therapeutics may advance the care of patients with postoperative ileus.

GOAT may be a therapeutic target for eating disorders or other metabolic diseases. Further work on how stomach GOAT is regulated could provide another important step in unraveling the effect of ghrelin on feeding and glucose homeostasis control, which will improve our understanding of obesity and its treatment. Identification of GOAT will facilitate the search for inhibitors that reduce appetite and diminish obesity in humans. First, to date, ghrelin is the only protein to be octanlated; inhibition of GOAT is unlikely to affect other proteins and may have effects only on the stomach. Second, small-molecule inhibitors of enzymes are generally more feasible to develop than small-molecule mimetics of peptide hormones. Hence, GOAT presents a novel therapeutic target. Future studies using GOAT-knockout mice and tissue-specific genetic ablation of GOAT will enable clarification of the paracrine roles of ghrelin in different tissues, and particular emphasis should be given to the stomach, pancreas, and hypothalamus (Gualillo et al., 2008).

As loss- and gain-of-function models prove their roles in modulating diet-induced adiposity, modulators of ghrelin–GHS–GOAT may be potential novel antiobesity drugs and anticachexia therapeutics. The development of therapy seems attractive and has potential, but it will be costly. Finally, we need to carefully define the “precise indications” for patients most likely to benefit from this treatment.

XIII. Conclusions

During the past decade, numerous gastrointestinally derived peptides have been associated with significant effects on food intake, gut motility, energy balance, and nutrition partition. Among these peptides, the breakthrough discovery of acyl ghrelin, another two ghrelin gene products (des-acyl ghrelin and obestatin), GHS-R1a, and GOAT is amazing and defy several well recognized, traditional biochemical principles. Acyl ghrelin, des-acyl ghrelin, obestatin, GHS-R, and GOAT just look like five pieces of the same puzzle, and investigation of them is extremely attractive and challenging. The ghrelin system has been one of the most extensively investigated gut peptides in the last decade, with more than 3862 publications in 10 years listed on PubMed. Acyl ghrelin not only strongly stimulates GH secretion but is also involved in energy homeostasis by eliciting food intake and promoting adiposity through a GH-indepedent mechanism. The ghrelin system has been shown to play a role in multiple physiological processes, including appetite regulation, metabolism, anxiety, and, more recently, dendritic spine architecture, long-term potentiation, and cognition.
In summary, acyl ghrelin, des-acyl ghrelin, obestatin, GHS-R, and GOAT may be part of a system with multiple effectors elements and constitutes the center of an integrated gut-brain energy axis, modulating appetite, digestion, gut motility, adiposity, and energy partition. Emerging groundbreaking fundamental advances in basic research could translate into potential therapies across many clinical specialties, including endocrinology, gastroenterology, cardiology, oncology, psychiatry, nutrition, and immunology. The investigation of ghrelin gene products and GHS-R1a and GOAT unrailes the pathogenesis of mammalian diseases and opens up new paradigms for drugs that can tackle multiple symptoms in various human disorders. Hence, ghrelin gene products, GHS-R, and GOAT may provide a range of therapeuetic opportunities to deliver a promising treatment of complex human diseases. Further research will answer and elucidate the biochemical and physiological characteristcs of this unique hormone system.

Acknowledgments. C.-Y.C. received the Great Academic Achievement Award at the 50th Anniversary of Taipei Veterans General Hospital, Taiwan, and was awarded a Clinical Physician Research Scholarship from the Department of Health, Taiwan.

REFERENCES


Am J Gastroenterol 100:1309–1313.


Graves RC19–RC22.


preparidinal ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 95:5344–5350.


The present study was supported by grants from the Ministry of Health, Labour, and Welfare of Japan (N0020, 087507–7512) and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (19790033 and 19070084 to J.O.).


pentapeptide inhibits the secretion of pancreatic juice in rats. 


GHRELIN GENE PRODUCTS IN FOOD INTAKE & GUT MOTILITY


Peres-Foncain M, Cordova F, Rodriguez-Carmona A, Petero J, Garcia-Naveiro R, and Garcia-A


Szintari M, Kapas L, and Krueger JM (2007a) Ghrelin microinjection into fore-
GHRELIN GENE PRODUCTS IN FOOD INTAKE & GUT MOTILITY

481


